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ABSTRACT 
We designed 39 new 2-phenylindole derivatives as potential anticancer agents bearing the 3,4,5-
trimethoxyphenyl moiety with a sulfur, ketone or methylene bridging group at position 3 of the indole 
and with halogen or methoxy substituent(s) at positions 4-7. Compounds 33 and 44 strongly inhibited 
the growth of the P-glycoprotein-overexpressing multidrug resistant cell lines NCI/ADR-RES and 
Messa/Dx5. At 10 nM, 33 and 44 stimulated the cytotoxic activity of NK cells. At 20-50 nM, 33 and 44 
arrested >80% of HeLa cells in the G2/M phase of the cell cycle, with stable arrest of mitotic 
progression. Cell cycle arrest was followed by cell death. Indoles 33, 44 and 81 showed strong 
inhibition of the SAG-induced Hedgehog signaling activation in NIH3T3 Shh-Light II cells with IC50’s 
of 19, 72 and 38 nM, respectively. Compounds of this class potently inhibited tubulin polymerization 
and cancer cell growth, including stimulation of natural killer cell cytotoxic activity and repression of 
Hedgehog-dependent cancer. 
  
INTRODUCTION 
Microtubules (MTs) are cylindrical structures mainly composed of α,β-tubulin heterodimers. MT 
assembly is a highly dynamic process because of continuous transitions between polymerization and 
depolymerization. MTs are involved in a number of essential cellular functions, such as maintenance of 
cell shape, cell motility, intracellular transport and cell division. Interfering with the MT dynamic 
equilibrium, by either inhibiting tubulin polymerization or blocking MT disassembly, prevents proper 
MT function and ultimately leads to cell death. Interfering with these cellular processes has resulted in 
a productive strategy for the development of efficient anticancer agents.1-4 
Colchicine (1),5,6 combretastatin A-4 (CSA4, 2)7 (Chart 1) and the Catharanthus alkaloids 
vincristine (VCR) and vinblastine (VBL) inhibit MT assembly by preventing tubulin polymerization, 
and this leads cell to death. In contrast, taxoids and epothilones bind at a luminal site on the -
subunit8,9 following entry into the MT through pores in its wall10 that are shaped by various tubulin 
subunits on the MT surface. Some evidence indicates a transient binding of MT stabilizing agents at a 
specific pore site. Paclitaxel (PTX) stimulates MT polymerization and stabilization at high 
concentrations, whereas lower concentrations of PTX inhibit MT dynamics with little effect on the 
proportion of tubulin in polymer.11 
The development of MT-targeting drugs with different mechanisms of action12 has achieved 
substantial progress. However, drug resistance, toxicity and unwanted side effects still remain unsolved 
problems. Therefore, the quest for new MT inhibitors as components of improved anticancer treatments 
remains mandatory.13 
Arylthioindole (ATI) derivatives are potent inhibitors of tubulin polymerization that bind to the 
colchicine site on -tubulin. A number of ATIs proved to be more potent than 1, 2, VBL, and PTX and 
thus are potential new anticancer agents.14,15 
 
Chart 1. General Structures of Compounds 1−45. 
 
 
ATI derivatives bearing an aromatic ring at position 2 of the indole (A region) inhibit tubulin 
polymerization and cancer cell growth. These compounds hamper mitotic progression, thus causing 
cells to undergo apoptosis (i.e., ATI 3: tubulin assembly IC50 = 3.3 M; MCF-7 IC50 = 52 nM)14,15 
(Chart 1). In contrast, chemical modification of positions 4-7 of the indole (D region) were not 
exhaustively explored, although a few ATI derivatives bearing an ethoxycarbonyl functionality at 
position 2 and a halogen atom or a methoxy group at position 5 proved to be potent tubulin assembly 
inhibitors (i.e., ATI 4: tubulin assembly IC50 = 2.0 M; MCF-7 IC50 = 13 nM).16 It should also be noted 
that major differences in structure-activity relationships (SAR) were found in comparing ATIs with the 
3-aroylindoles reported by Hsieh and co-workers.17 These compounds are characterized by the 
presence of a methoxy group at position 6 of the indole. 
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 Figure 1. Proposed binding modes of 1 (cyan), 3 (gray) and 44 (orange). Tubulin is represented as a cartoon for the - (red) and - (green) subunits. Residues forming interactions with the ATI D region are depicted in white. 
 
Docking studies of compounds 1 and 3 into the colchicine site of tubulin showed a good 
superimposition of the trimethoxyphenyl (TMP) moieties and of the tropolone ring C with the phenyl 
core of the indole14,15 (Figure 1). These findings suggested that appropriate substituents at positions 4-7 
of the indole could resemble the methoxy and carbonyl groups at positions 10 and 9, respectively, of 
the tropolone ring. Docking simulations with PLANTS,18 using our methodology described 
previously,19 revealed binding poses consistent with the previous ATI series: (i) the TMP group formed 
polar interactions with  βCys241, βMet259 and βLeu255ν (ii) the indole NH established an H-bond 
with αThr179ν (iii) the phenyl ring at position 2 of the indole set up hydrophobic interactions with the 
βLys254 and βLeu248 side chains. In comparison with 3, the chlorine atom(s) of 10, 18, 28, 37 and 44 
fitted into a new hydrophobic pocket formed by the Lys353, Asn258, Met259 and 
residue side chains (Figure 1S, Supporting Information). The 7-fluoro atom of 40, the most potent 
tubulin polymerization inhibitor within the series, behaved as a H-bond acceptor with Val181 (Figure 
2S, Supporting Information). The methoxy group of 33 mimicked the corresponding group at position 
10 of 1, resembling its interaction with the N of Lys353.  
Scheme 1. Synthesis of Compounds 6-45. 
 
6, 7, 46, R = 4-Br; 8-10, 47, R = 4-Cl ; 11, 12, 48, R = 4-F; 13, 14, 
49, R = 4-OMe; 15-17, 50, R = 5-Br; 18-20, 51, R = 5-Cl; 21, 22, 
52, R = 5-F; 23-25, 53, R = 5-OMe; 26, 27, 54, R = 6-Br; 28-30, 
55, R = 6-Cl; 31, 32, 56, R = 6-F; 33, 34, 57, R = 6-OMe; 35, 36, 
58, R = 7-Br; 37-39, 59, R = 7-Cl; 40, 41, 60, R = 7-F; 42, 43, 61, 
R = 7-OMe; 44, 45, 62, R = 6,7-Cl2. 
 
aReagents and reaction conditions: (a) bis-(3,4,5-
trimethoxyphenyl)disulfide, anhydrous DMF, closed vessel, 
130 °C, 120 W, 2 min, venting-while-heating, 20-77%; (b) 3,4,5-
trimethoxybenzoyl chloride, anhydrous AlCl3, 1,2-
dichloroethane, closed vessel, 110 °C, 150 W, 2 min, 20-78%; 
(c) (10, 20, 25, 30 and 39) borane tetrahydrofuran complex, 
acetonitrile/methanol, 50 °C, 1 h, 10-41%; (d) (17) 
triethylsilane, trifluoroacetic acid, 1,2-dichloroethane, 250 °C, 
250 W, 20 min, 15%. 
  
 
These observations prompted us to undertake SAR investigations at positions 4-7 of the indole 
(Chart 1 and Table 1). We planned the synthesis of 2-phenyl-1H-indole derivatives, keeping the 2-
phenyl group fixed at position 2, because of the better metabolic profile compared to indole derivatives 
bearing an ester function at this position.15 
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CHEMISTRY 
2-Phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indoles 6, 8, 11, 13, 15, 18, 21, 23, 25, 28, 31, 33, 35, 
37, 40, 42 and 44 were prepared by reacting 2-phenylindoles 46-62 with bis-(3,4,5-
trimethoxyphenyl)disulfide16 in the presence of sodium hydride at 130 °C (120 W) for 2 min according 
to our previously reported venting-while-heating microwave-assisted procedure20 (Scheme 1). 
Microwave-assisted Friedel-Crafts reaction of the indoles 46-62 with 3,4,5-trimethoxybenzoyl chloride 
in the presence of AlCl3 in 1,2-dichloroethane at 110 °C (150 W) for 2 min furnished the corresponding 
methanones 7, 9, 12, 14, 16, 19, 22, 24, 27, 29, 32, 34, 36, 38, 41, 43 and 45.21 Methylene derivatives 
10, 17, 20, 25, 30 and 39 were prepared by reducing the appropriate ketones with borane 
tetrahydrofuran complex in acetonitrile/methanol at 50 °C for 1 h22 (10, 20, 25, 30 and 39) or with 
triethylsilane/trifluoroacetic acid in 1,2-dichloroethane at 250 °C (250 W) for 20 min23 (17).  
Reaction of the appropriate 1-methyl-2-nitrobenzene with benzaldehyde in the presence of sodium 
ethoxide in anhydrous dimethyl sulfoxide at 25 °C for 12 h furnished the alcohols 63-65. After 
oxidation of 63-65 to ketones 66-68 with pyridium chlorochromate in anhydrous dichloromethane at 
25 °C for 1.5 h, the nitro group was reduced to amino with tin(II) chloride dihydrate/1 N HCl in acetic 
acid at reflux temperature for 12 h; the intermediate aminoketone underwent intramolecular cyclization 
to give the corresponding 2-phenylindoles 46, 54 and 56 (Scheme 2a).24 2-Phenylindoles 47-49, 55, 57 
and 61 were prepared by reaction of the N-(2-tolyl)benzamides 69-74 with tert-butyllithium in 
anhydrous tetrahydrofuran at -40 °C.25 Amides 69-74 were obtained by treatment of an appropriate 
ortho-toluidine with benzoyl chloride in the presence of triethylamine in anhydrous tetrahydrofuran at 
reflux temperature for 2 h (Scheme 2b). Polyphosphoric acid-mediated cyclization at 110 °C for 1 h of 
phenylhydrazones 75-80, prepared from the appropriate phenylhydrazine hydrochloride and 
acetophenone in the presence of sodium acetate in ethanol at 80 °C (250 W) for 5 min,26 gave the 
corresponding 2-phenylindoles 50-52, 58, 60 and 6227 (Scheme 2c). 
 Scheme 2. Synthesis of Intermediates 46-62.a 
 
 
63, 66, R = 2-Br; 64, 67, R = 4-Br; 65, 68, R = 4-F; 69, R = 3-Cl; 
70, R = 3-F; 71, R = 3-OMe; 72, R = 5-Cl; 73, R = 5-OMe; 74, R = 
2-OMe; 75, R = 4-Br; 76, R = 4-Cl; 77, R = 4-F; 78, R = 2-Br; 79, 
R = 2-F; 80, R = 5,6-Cl2. 
 
aReagents and reaction conditions: (a) benzaldehyde, sodium 
ethoxide, anhydrous DMSO, 25 °C, 12 h, 40-44%; (b) pyridium 
chlorochromate, anhydrous dichloromethane, 25 °C, 1.5 h, 16-
40%; (c) tin(II) chloride dihydrate/1 N HCl, acetic acid, reflux 
temperature, 12 h, 19-24%; (d) benzoyl chloride, triethylamine, 
anhydrous THF, reflux temperature, 2 h, 49-88%; (e) (i) tert-
butyllithium, anhydrous THF, 40 °C, Ar stream; (ii) 1 h, 0 °C; 
(iii) 25 °C, 12 h, 18-52%; (f) acetophenone, sodium acetate, 
ethanol, open vessel, 80 °C, 250 W, 5 min, cooling-while-heating, 
25-95%; (g) polyphosphoric acid, 110 °C, 1 h, 25-82%. 
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RESULTS AND DISCUSSION 
Inhibition of Tubulin Polymerization, the Binding of Colchicine to Tubulin and MCF-7 Breast 
Cancer Cell Growth. We synthesized compounds 6-45, including ATI derivatives and some 
corresponding ketone and methylene compounds, to obtain SAR information on the substituent(s) 
introduced at positions 4-7 of the indole nucleus. The activities of compounds 6-45 as inhibitors of 
tubulin polymerization in vitro, the growth of MCF-7 human breast cancer cells and the binding of 
[3H]colchicine to tubulin are shown in Table 1. The majority of these new derivatives (23 compounds: 
8, 11, 12, 15, 18, 21, 26-30, 33-38 and 40-45) inhibited tubulin polymerization with IC50 values in the 
1.0−2.0 ȝM range, as compared with colchicine (1) (IC50 = 3.2 ȝM) and CSA4 (2) (IC50 = 1.0 ȝM). 
Among the group of compounds 6-14, bearing the substituent at position 4 of the indole, the 4-
chloro derivative 8 inhibited tubulin assembly with an IC50 of 1.6 ȝM and was 2.2-fold more active  
than corresponding ketone 9 (IC50 = 3.6 ȝM). The thio/keto 4-fluoro derivatives 11 (IC50 = 1.7 ȝM) and 
12 (IC50 = 1.6 ȝM) were almost equipotent as tubulin assembly inhibitors and showed the greatest 
inhibition of MCF-7 cell growth (11, IC50 = 80 nM, and 12, IC50 = 65 nM). Neither the bromine atom 
nor the methoxy group were found among the most active compounds with position 4 substituents in 
both the thio and ketone series. In terms of effects on MCF-7 cell growth, there is no evident major 
difference between the thio and keto series with substituents at position 4, although the data are limited. 
Compounds 15-25 were characterized by substituents at position 5 of the indole nucleus. As tubulin 
polymerization inhibitors, the arylthioindoles 15 (IC50 = 1.3 ȝM), 18 (IC50 = 1.5 ȝM), 21 (IC50 = 1.5 
ȝM) and 23 (IC50 = 2.1 ȝM) were all significantly more potent than the corresponding ketones 16, 19, 
22 and 24 and slightly more active than the methylene compounds 17, 20 and 25. The tubulin 
inhibitory activity of these compounds seemed to be weakly affected by the nature of the substituent. In 
contrast to the corresponding ester derivatives, all these compounds were weak inhibitors of MCF-7 
cell growth with IC50’s ≥100 nM (compare 4 (IC50 = 13 nM) with 23, and 5 (IC50 = 42 nM) with 18). 
Further, within the limitations of the data, there are no major differences in effects on MCF-7 cell 
growth dependent on the bridging group (thio, ketone or methylene). 
Compounds 26-34, bearing the substituent at position 6, inhibited tubulin polymerization with IC50’s 
< 2.5 µM, with the exception of the 6-fluoro derivative 32 (IC50 = 10 µM). As inhibitors of MCF-7 cell 
growth, ketones were less potent than the corresponding thio derivatives. Among the thio derivatives, 
the 6-bromo- (26, IC50 = 9.0 nM) and 6-methoxy- (33, IC50 = 1.3 nM) derivatives were the most potent 
cell growth inhibitors. Compounds 35-43, with the substituent at position 7 of the indole, were all 
potent inhibitors of tubulin assembly, with IC50’s < 2.5 µM. With the exception of 39 and 43, these 
compounds potently inhibited the growth of the MCF-7 cells, with compounds 36 (IC50 = 4 nM) and 38 
(IC50 = 9 nM) being the most active. In contrast to the findings with the 6-substituted indoles, in the 7-
substituted series, the bromo and chloro ketones tended to be more potent than the corresponding thio 
counterparts as inhibitors of MCF-7 cell growth (compare 26, 27 with 35, 36; and 28, 29 with 37, 38). 
Finally, we tried to join the features of 28, 29 with those of 37, 38 to further enhance activity. This 
effort yielded the 6,7-dichloroindole derivatives 44 and 45, both of which indeed were highly potent 
inhibitors of tubulin polymerization (IC50 = 1.2 and 1.5 ȝM, respectively) and MCF-7 cell growth (IC50 
= 7 and 15 nM, respectively). SAR summary of tubulin polymerization inhibition (TPI) and inhibition 
of MCF-7 cell growth of ATI derivatives 6-45 is depicted in Figure 2. 
The results obtained from the docking simulations described above, provided us with a general 
binding mode that was able to justify the biological activity of the compounds. However, there were 
some exceptions that could not be fully rationalized (7, 13, 14 and 16) and we did not see any 
correlation between docking scores and experimental data. This has prompted us to further investigate 
the binding mode of ATIs with another set of docking simulations using a more recent tubulin structure 
(pdb code 4O2A),29 crystallized at higher resolution than the structure used previously (2.50Å vs 3.58Å 
respectively).29 Furthermore, we have performed the docking calculations with two other software that 
each rely on a different search algorithm: Glide30 and Autodock.31 
The docking results obtained from these simulations were entirely consistent with the one obtained 
using PLANTS. Indeed, we observed a virtually identical binding pose for the ATIs, regardless of the 
tubulin structure or the algorithm used in the simulation (Figure 3S, Supporting Information). It should 
be noted that we have not observed any correlation between the docking score and the experimental 
data in any of the calculations (Table 1S, Supporting Information). This observation is not entirely 
surprising considering this correlation is rarely observed.28   
We analyzed the data from Table 1 comparing the microtuble assembly inhibitory concentrations 
affinity of the compounds for the colchicine site (Figure 3). The inhibition of tubulin polymerization 
was in good agreement with inhibition of colchicine binding. The compounds that inhibited tubulin 
assembly with IC50 values in the 1.0-1.5 µM range, inhibited colchicine binding by 39-96% (mean 
value of 79%); those that inhibited assembly with IC50’s in the 1.6-2.0 µM range, inhibited colchicine 
binding by 48-82% (mean value of 70%); and assembly inhibitors with IC50’s in the 2.1-3.0 µM range, 
inhibited colchicine binding by 33-74% (mean value of 53%) (CSA4: assembly IC50 = 1.0 µM, 
colchicine binding inhibition = 98%). We analyzed the MCF-7 cell growth inhibition (nM) of ATIs 6-
45 with the corresponding inhibitory concentration (M) on tubulin assembly (Panel A, Figure 4S, 
Supporting Information) and with % inhibition on the binding of [3H]colchicine to tubulin (Panel B, 
Figure 4S, Supporting Information). In these plots we observed good correlation of the antiproliferative 
data with the biochemical data, particularly with the ligand binding data (inhibition of colchicine 
binding). 
 
 
 
  
Figure 2. SAR summary of tubulin polymerization 
inhibition (TPI) and inhibition of MCF-7 cell growth of 
ATI derivatives 6-45. 
 
 
 
Figure 3. Correlation between tubulin assembly (IC50 values, μM) and inhibition of colchicine binding 
(% values). Data of ATI derivatives 6-45 are shown as open circles. Black circle represents CSA4 as 
reference compound. 
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Table 1. Inhibition of Tubulin Polymerization, Binding of Colchicine to Tubulin and Growth of MCF-7 
Human Breast Carcinoma Cells by Compounds 6-45 and References 1-5. 
 
 
 
compd R X 
Tubulin Assemblya 
IC50 ± SD 
(M) 
MCF-7b,c 
IC50 ± SD 
(nM) 
Colchicine 
Bindingd 
(% ± SD) 
6 4-Br S 2.4 ± 0.1 400 ± 70 33 ± 2 
7 4-Br C=O >20 (partial activity)e 430 ± 100 nd 
8 4-Cl S 1.6 ± 0.07 290 ± 50  48 ± 5 
9 4-Cl C=O 3.6 ± 0.2 260 ± 50 38 ± 3 
10 4-Cl CH2 17 ± 0.2 >5000 ndf 
11 4-F S 1.7 ± 0.07 80 ± 30 80 ± 0.4 
12 4-F C=O 1.6 ± 0.08 65 ± 7 63 ± 1 
13 4-MeO S >20 (partial activity) e 1400 ± 300 nd 
14 4-MeO C=O >20 (no activity)g >5000 nd 
15 5-Br S 1.3 ± 0.1 320  ± 100 39 ± 3 
16 5-Br C=O >40 530  ± 100 nd 
17 5-Br CH2 4.0 ± 0.5 700  ± 300 31 ± 2 
18 5-Cl S 1.5 ± 0.2 280 ± 70 49 ± 5 
19 5-Cl C=O >20 330 ± 100 nd 
20 5-Cl CH2 4.4 ± 0.8 310 ± 10 38 ± 3 
21 5-F S 1.5 ± 0.1 300 ± 0 61 ± 4 
22 5-F C=O 13 ± 0.4 240 ± 90 nd 
23 5-OMe S 2.1 ± 0.01 200 ± 80 58 ± 0.5 
24 5-OMe C=O 8.3 ± 1 170 ± 60 nd 
25 5-OMe CH2 3.5 ± 0.4 100 ± 0 41 ± 0.9 
N
H
X
OMe
OMe
OMe
R
6-45
26 6-Br S 1.9 ± 0.2 9.0 ± 2 87 ± 0.6 
27 6-Br C=O 1.3 ± 0.2 30 ± 2 86 ± 0.4 
28 6-Cl S 1.2 ± 0.2 20 ± 10  88 ± 3 
29 6-Cl C=O 1.4 ± 0.06 35 ± 7 71 ± 5 
30 6-Cl CH2 1.6 ± 0.01 55 ± 20 72 ± 6 
31 6-F S 2.4 ± 0.2 80 ± 20 74 ± 2 
32 6-F C=O 10 ± 0.4 600 ± 0 nd 
33 6-MeO S 1.1 ± 0.1 1.3 ± 0.6 96 ± 1 
34 6-MeO C=O 1.2 ± 0.06 30 ± 10 95 ± 0.4 
35 7-Br S 1.6 ± 0.2 25 ± 5 82 ± 1 
36 7-Br C=O 1.7 ± 0.1 4.0 ± 0.5 72 ± 0.3 
37 7-Cl S 1.3 ± 0.2 50 ± 10  82 ± 0.3 
38 7-Cl C=O 1.8 ± 0.05 9.0 ± 1 69 ± 0.5 
39 7-Cl CH2 2.4 ± 0.2 200 ± 0 50 ± 4 
40 7-F S 1.0 ± 0.1 20 ± 9 92 ± 0.3 
41 7-F C=O 1.7 ± 0.1 30 ± 0 67 ± 3 
42 7-OMe S 1.2 ± 0.01 19 ± 10 87 ± 2 
43 7-OMe C=O 1.8 ± 0.1 200 ± 0 62 ± 3 
44 6,7-Cl2 S 1.2 ± 0.1 7.0 ± 3 92 ± 2 
45 6,7-Cl2 C=O 1.5 ± 0.03 15 ± 5 93 ± 0.7 
1 — — 3.2 ± 0.4 5.0 ± 1 nd 
2 — — 1.0 ± 0.1 13 ± 3 98 ± 0.6 
3h — — 3.3 ± 0.1 52 ± 7 nd 
4i — — 2.0 ± 0.2 13 ± 3 93 ± 0.8 
5i — — 2.5 ± 0.3 42 ± 10 76 ± 0.2 
 
aInhibition of tubulin polymerization. Tubulin was at ͳͲ μM in the assembly assay. bInhibition of growth of MCF-7 
human breast carcinoma cells. cCompounds that inhibited tubulin assembly with IC50 ≤ͷ μM were tested in the 
cellular and colchicine binding assays. dInhibition of [3H]colchicine binding. Tubulin was at ͳ μM. Both 
[3H]colchicine and inhibitor were at ͷ μM. ePartial inhibition at 20 µM. fNo data. gLittle or no activity at 20 M. 
hLit.
15. iLit.
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 Table 2. Growth Inhibition of MDA-MB-468, MDA-MB-436, MDA-MB-231, A-549, MV4-11, NB4 and NCI-H1975  
Cell Lines by Compounds 33 and 44 and Reference PTX. 
 
 IC50 ± SD  
 
compd 
MDA- 
MB-468a 
MDA- 
MB-436a 
MDA 
MB-23a 
MV4-11b 
(AML_M9)  
NB4b 
(AML_M3) 
 
A-549a 
NCI- 
H1975a 
33 37 ± 0.5 62 ± 1 39 ± 1.2 2.5 ± 2.1 4 ± 1 28 ± 6 195 ± 158 
44 33 ± 0.3 75 ± 1.1 47 ± 0.1 10.5 ± 0.7 10 ± 4 120 ± 10 305 ± 122 
PTX  5 ± 1 8 ± 1.5 7 ± 2 ndb 2.3 ± 0.3 7 ± 2 2.5 ± 5 
aIncubation time was 72 h. bIncubation time was 48 h. bNo data. 
 
 
 
Cell Growth Inhibition. ATIs 33 and 44 were assayed as growth inhibitors of a panel of cancer cell 
lines, including MDA-MB-468, MDA-MB-436, MDA-MB-231, A-549, MV4-11, NB4 and NCI-
H1975, using PTX as reference drug. As a growth inhibitor of MDA-MB-468, MDA-MB-436, and 
MDA-MB-231 breast cancer cells, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay, ATI 33 at 72 h showed IC50 values of 37, 62 and 39 nM, respectively, with the 
corresponding values for 44 being 33, 75 and 47 nM, respectively (Table 2). Compounds 33 and 44 
induced a dose and time-dependent growth inhibition of each treated cell line (Figures 5S-10S, 
Supporting Information). Compounds 33 and 44 inhibited the human acute myelocytic leukemia 
(AML) cell lines MV4-11 and NB4, showing at 48 h IC50’s of 2.5 and 10.5, and 4 and 10 nM, 
respectively. As growth inhibitors of the A-549 and NCI-H1975 human lung adenocarcinoma cancer 
cells bearing the KRAS mutation and resistance to EGFR inhibitors, respectively, ATIs 33 and 44 
yielded at 72 h  IC50 values in the nanomolar concentration range. 
 
 
Table 3. Inhibition of Growth of the OVCAR-8 and NCI/ADR-RES, and Messa and 
Messa/Dx Cell Line Pairs by Compounds 33 and 44, and Reference Compounds 1, 
2, VRB, VBL and PTX.a 
 
  IC50 ± SD  (nM)  
compd OVCAR-8 NCI/ADR-RES   Messab Messa/Dx5b 
33 4.3 ± 1 2.5 ± 1 20.7 ± 1.7 28.0 ± 1.0 
44 14 ± 2 10 ± 4 3.5 ± 0.9 4.5 ± 1.9 
1 30 ± 1 420 ± 100 11 ± 6 329 ± 166 
2 2.8 ± 1 1.8 ± 1 2.7 ± 2 2.6 ± 1 
VRB 300 ± 0 5000 ± 1000 ndc nd 
VBL 15 ± 7 200 ± 0 3 ± 2 144 ± 61 
PTX 3.7 ± 1 6000 ± 500 4 ± 1 1764 ± 477 
aInhibition of growth of the indicated cell lines. bIncubation time was 72 h. cNo data. 
 
 
 
Multidrug Resistant (MDR) Cell Lines. Compounds 33 and 44 were evaluated as inhibitors of the 
ovarian carcinoma cell lines OVCAR-8 and its cognate P-glycoprotein (Pgp) overexpressing line 
NCI/ADR-RES and of the human uterine sarcoma cell line Messa and its cognate MDR line 
Messa/Dx5, using 1, 2, vinorelbine (VRB), VBL and PTX as reference compounds (Table 3). The 
reference agents 1, VRB, VBL and PTX weakly inhibited these MDR cell lines. Compounds 33 and 44 
and the reference 2 were potent inhibitors of the MDR cell lines. ATI 33 (IC50 = 2.5 ± 1 nM) was 
comparable to 2 (IC50 = 1.8 ± 1 nM) as an inhibitor of the NCI/ADR-RES cell line, and 44 (IC50 = 4.5 
± 1 nM) was comparable to 2 (IC50 = 2.6 ± 1 nM) in the Messa/Dx5 cells. 
Arrest of Mitotic Progression and Concomitant Cell Death Induction.  To assess whether the 
growth suppressive effect of 33 and 44 reflected their antimitotic activity, we assessed their ability to 
induce mitotic arrest. We previously found that treatment with 20 nM VBL effectively arrested the cell 
cycle of HeLa cells in mitosis; at lower concentrations VBL did not fully prevent mitotic progression, 
such that cells assemble defective mitotic spindles, “slip” through the mitotic checkpoint and progress 
towards aberrant chromosome segregation.14 We examined HeLa cell cultures treated with 20, 50 and 
100 nM 33 or 44 in DMSO, 20 nM VBL or DMSO vehicle. Treatments were carried out for 24 h, 
allowing all cells to enter mitosis during the treatment. Cell cultures were then harvested, and their cell 
cycle profile was analyzed by flow cytometry after incubation with propidium iodide (PI) to reveal 
their genomic DNA content (linear scale). ATIs 33 and 44 at 20 nM induced >80% of HeLa cells to 
arrest with a G2/M genomic content, similar to VBL; very few cells progressed past the G2/M phase 
(Figure 4A). Thus, both 33 and 44 effectively arrested mitotic progression and prevented mitotic 
slippage, and hence the generation of hyperdiploid or polyploid cells. To assess whether G2/M-arrested 
cells underwent cell death over time, PI-stained cell samples were analyzed by plotting their DNA 
content on a logarithmic scale to resolve the sub-G1 region, in which hypodiploid cells represent the 
terminal products of cell death. ATIs 33 and 44 at 20 nM induced both cell death and concomitant 
G2/M phase arrest and were comparable to VBL; these effects were even more substantial at 50 nM 
(Figure 4B). The induction of cell death by 33 seemed to be superior to 44 at all tested concentrations. 
Biparametric analysis after simultaneous incubation of non-permeabilized cells with annexin V, which 
reacts with phosphatidylserine residues on the outer cell membrane during early apoptosis, and PI, to 
which viable cells are not spontaneously permeable, discriminates early and late stages of apoptotic cell 
death (Figure 4C) from necrotic cells, which are permeable to PI but do not react with annexin V. We 
found that 33 and 44 induced cell death with apoptotic-like phenotypic features with comparable 
effectiveness and early-to-late kinetics as observed with VBL.  
 
 Figure 4. A. Cell cycle profiles of HeLa cell cultures exposed to 33, 44 or VBL for 24 h at the indicated 
concentrations; the % of cells with 2C (G1 phase, black bars), 4C (G2/M phases, white bars), or between 2C and 4C (S 
phase, dashed bars) genomic DNA content is shown. Mean values were calculated from three independent 
experiments. B. Flow cytometry analysis of PI-stained cells with sub-G1 DNA content, representing terminal cell 
death, after 24 h. Mean values were calculated from four independent experiments. C. Distribution of cells 
simultaneously processed for annexin V reactivity and PI incorporation, representing early (reactive to annexin V, 
not permeable to PI) and late (reactive to both annexin V and PI) stages of the cell death process in cultures treated 
for 24 h. Mean values were calculated from three independent experiments. 
 
 
 Figure 5. Mitotic phenotypes in HeLa cell cultures exposed to ATIs 33 and 44 for 24 h and processed for IF to 
tubulin (in red). The bar graph on the left indicates the statistical distribution of the cytological phenotypes depicted 
under the indicated conditions; the frequency of scored phenotypes is shown as % of all counted mitotic figures (330 
to 400 counted mitotic figures per condition). Grey bars represent the frequency of mitotic cells with severe 
inhibition of tubulin polymerization, with no recognizable MTs and unstructured tubulin aggregates (exemplified in 
the top IF panel). Purple bars represent the frequency of mitotic cells with inhibited MT polymerization, yielding 
short MT stretches (middle panel). Black bars represent the frequency of normal mitoses with polymerized MT 
arrays forming a bipolar spindle (bottom panel). 
 
 
 
 
ATIs 33 and 44 Strongly Inhibit Mitotic MT Assembly. To correlate cell cycle arrest and cell 
death induction with inhibition of MT dynamics in HeLa cells, we employed immunofluorescence (IF) 
to examine the effects of ATIs on tubulin and MTs. HeLa cells were treated with 20 or 50 nM 33 or 44 
for 24 h, the same conditions that induced cell cycle arrest (Figure 4), then processed for tubulin IF and 
examined under fluorescence microscopy. We found that at both concentrations 33 or 44 arrested cells 
in mitosis with a prometaphase-like appearance. Consistent with the absence of hyperdiploid cells in 
flow cytometry analysis, both ATIs at 20 nM or higher effectively prevented mitotic slippage. At 20 
nM, the ATIs inhibited MT polymerization and left tubulin foci and/or small asters of short MT 
fragments (an example is shown in Figure 5A, middle panel). The proportion of mitotic cells displaying 
this inhibited MT phenotype was very similar to that observed with VBL (Figure 5B). Raising the ATI 
concentrations to 50 nM yielded a phenotype with no recognizable mitotic MT remnants, but only 
tubulin aggregates that formed an unstructured meshwork throughout the mitotic cells (Figure 5A, top 
panel). In summary, the newly synthesized ATIs strongly affect cellular MT polymerization, resulting 
in effective inhibition of formation of the mitotic apparatus, particularly when used at 50 nM, and this 
phenotype was associated with a durable mitotic arrest and concomitant induction of cell death. 
Inhibition of PC-3, RD, and HepG2 Cancer Cell Growth. We determined the effects of ATIs 33 
and 44 as growth inhibitors of the human prostate cancer PC-3, rhabdomyosarcoma RD and human 
liver hepatocellular carcinoma HepG2 cell lines, with VBL and PTX as reference compounds (Table 4). 
ATIs 33 and 44 strongly inhibited these cell lines at nanomolar concentrations and were superior to the 
references VBL and PTX. Compound 33 was generally more effective than 44 as an inhibitor of the 
growth of these three cell lines. 
PC-3, RD, and HEPG2 cell cultures were treated for 24 h with increasing concentrations of ATIs 33 
and 44 and of PTX as reference drug at 500, 1000, and 2000 nM. After treatment, cells and vehicle 
controls (0.1% DMSO) were incubated with PI to analyze their DNA content in flow cytometry assays. 
Both ATIs arrested cell cycle progression in all three cell lines at low concentrations. ATIs 33 and 44 
induced an accumulation in the G2/M phase in PC-3 and RD cells, as did PTX, whereas in HepG2 cells 
these compounds caused a stronger effect on cell cycle progression as compared with the reference 
drug (Figure 11S, Supporting Information). 
 
 
 
 Table 4. Growth Inhibition of PC-3, RD and HepG2 Cell Lines 
by Compounds 33 and 41 and References VBL and PTX. 
 
 
IC50 ± SD a 
compd PC3 RD HepG2 
33 0.3 ± 0.06 0.2 ± 0.04   0.1 ± 0.02    
44 19 ± 1 16 ± 1.3 62 ± 2 
VBL 766 ± 1000  53 ± 2.5 81 ± 2.4 
PTX  4900 ± 1.3 >10000 2600 ± 1,5 
aIncubation time was 48 h. 
 
 
 
After a 24 h exposure and subsequent incubation in drug-free medium for 24 h, the PC-3, RD, and 
HepG2 cell lines treated with 33 or 44 showed a strong accumulation of cells in G2/M (Figure 6). 
Moreover, 33 and 44 induced an irreversible cell cycle arrest at the concentrations of 500, 1000, and 
2000 nM in the PC-3 and RD cells.  
A correlation between cell cycle arrest and cell death was investigated by exposing the cells to a 
500, 1000 or 2000 nM concentration of 33, 44 or PTX, followed by incubation with fluorescently 
conjugated annexin V and PI (Figure 7). All the cell lines treated with 33 or 44 at 500 nM showed 
higher rates of cell death than the same populations treated with 500 nM PTX. A dose-response trend in 
cell death was observed in the RD cell line after a 48 h exposure with either 44 or 33 (Figure 7B) and in 
the PC3 and HepG2 cell lines following treatment with PTX (Figure 7A and 7C).  
 
 
 
 Figure 6.  Cell cycle analysis of PC-3 (A), RD (B) and HepG2 (C) cells treated with 0.1% DMSO or 500, 1000 or 2000 
nM 33, 44 or PTX for 24 h, followed by a 24 h recovery in drug-free medium. Histograms represent % of cells with 
G0/G1, S and G2/M DNA content expressed as mean values ± SD of three independent experiments.  
 
 
 Figure 7. Cell death cytometric analysis of PC-3 (A), RD (B) and HepG2 (C) cells treated with 0.1% DMSO or 500, 1000 
or 2000 nM 33, 44 or PTX for 48 h. Flow cytometric profiles of cell populations following treatment with DMSO or 
2000 nM 33 or 44 are at the top of each panel (annexin-V-FITC staining on the x axis and PI on the y axis). Histograms 
represent % of cells in early apoptosis (annexin V-FITC staining) and late apoptosis (annexin V-FITC and PI staining) 
expressed as mean values ± SD calculated from three independent experiments.  
 
 Inhibition of T98G and U343MG Cancer Cell Growth. Malignant gliomas develop from gradual 
accumulation of multiple genetic alterations, resulting in either activation of oncogenes or inactivation 
of tumor suppressor genes.32 Human glioblastoma multiforme T98G and U343MG cells show typical 
hallmarks of glioblastoma multiforme tumors in patients. We evaluated the ability of compounds 33 and 
44 to inhibit the growth of T98G and U343MG cancer cells, which show different genetic profiles for 
the expression of key cell survival proteins, such as p53, MDM2, EGFR, RB, cyclin D, and MMPs.33 
Treatment of T98G and U343MG cells with increasing concentrations of 33 or 44 for 24, 48 or 72 h 
significantly inhibited cell growth in a dose- and time-dependent manner (Figures 12S and 13S, 
Supporting Information). The IC50 values were calculated taking into account the relative doubling time 
(CDT).34,35 after 48 h for the T98G cells and after 72 h for the U343MG cells. As a cell growth inhibitor, 
compound 33 yielded IC50 values of 15.2 ± 1.6 nM in T98G cells, and 0.5 ± 0.05 nM in U343 cells; for 
44, IC50 values of 16.3 ± 1.5 nM nM in T98G cells and 0.6 ± 0.05 nM nM in U343 cells were obtained. 
Expression of MICA and MICB ligands in HeLa Cells, Resulting in Enhanced Natural Killer 
(NK) Cell Degranulation.  In previous studies,36 treatment of HeLa and HepG2 tumor cell lines with 
sodium butyrate, a potent repressor of histone deacetylases that causes spindle abnormalities and 
mitotic arrest, resulted in up-regulation of the expression of NK cell receptor activating ligand MICA 
and MICB at both the mRNA and protein levels and in enhanced susceptibility of both cell lines to NK 
lysis. We evaluated the expression of NKG2D and DNAM-1 ligands in HeLa cells after treatment with 
either ATI 33, 37 or 44, in particular whether the compounds could modulate their expression. We first 
characterized HeLa cell growth inhibition by 33, 37 or 44, at a sub-lethal concentration after a 48 h 
treatment (MTT assay). HeLa cells were more sensitive to 33 and 44 (IC50 value = 10 nM) than to 37 
(IC50 = 76 nM). After a 48 h treatment with 10 nM ATI, flow cytometric biparametric analysis of HeLa 
cells by annexin V/PI staining showed only a weak increase of early apoptotic cells compared to 
control cultures (Figure 14S, Supporting Information). 
 Figure 8. ATIs 33, 37 and 44 up-regulate DNAM-1 and NKG2D ligands in HeLa cells. NKG2D and DNAM-1 ligand 
surface expression was analyzed by flow cytometry after a 48 h treatment with the indicated ATI compound. Data 
are representative of one out of three independent experiments. 
 
 
 
NK cell receptor activating ligand analysis by combined IF and flow cytometry revealed a different 
modulation of NKG2D and DNAM-1 ligands in ATI-treated HeLa cells after a 48 h treatment with 
sub-lethal doses. ATI  33, 37 or 44 behaved as strong enhancers of MICA, ULBP3 and PVR expression, 
while treatment with the compounds had weaker effects on MICB, ULBP1 and ULBP2 ligand 
expression (Figure 8) and no effect on the expression of the Nec-2 ligand (data not shown). 
Interestingly, (1-(3-aminophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone, a potent tubulin 
polymerization inhibitor belonging to the ARAP class,37 was unable to induce the NKG2D and 
DNAM-1 ligands  (data not shown). The expression of ligand surface on treated HeLa cells was not 
accompanied by a corresponding increase in mRNA levels, as indicated by real-time PCR data (Figure 
15S, Supporting Information).  
 
 
  
 
 
Figure 9. NK cell-mediated killing of HeLa cells increased after a 48 h treatment with ATI 33 or 44. Results are 
expressed as % of CD107a+ cells after subtraction of the % of the control antibody and represent one of two 
independent experiments. The basal CD107a expression on NK cells was about 2%. 
 
 
Based on these findings, we evaluated whether ATIs 33 and 44 would increase NK-cell 
degranulation towards HeLa cells. The expression of the lysosomal marker CD107a, which correlates 
with NK cell cytotoxicity,38 was evaluated by IF and flow cytometry analysis by gating on NK cells 
upon their interaction with treated or untreated HeLa cells, used as targets. The up-regulation of 
NKG2D and DNAM-1 ligands was verified before the degranulation assay (data not shown). The 
expression of CD107a on NK cells contacting treated-HeLa target cells indicated that those cells were 
more susceptible to NK cell lysis (Figure 9). 
Hedgehog Inhibiting Activity. Hedgehog (Hh) signaling pathway is deeply involved in 
tumorigenesis, and inhibitors of the Hh pathway have shown great potential as cancer therapeutics. In 
recent years, an ever growing interest in the Hh pathway has led to the development of a variety of 
small molecules targeting key Hh components, i.e., Smoothened (Smo), Sonic hedgehog protein (Shh), 
and Gli1.39 Currently, some antagonists of Smo, the positive signaling transducer in Hh pathway, are 
undergoing clinical trials. 
 
  
Figure 10. Inhibition of endogenous Hh signaling in Shh-L II cells by 33, 44 and 81. Dose–response curve of the 
indicated compounds in SAG-treated cells in comparison with untreated Shh-Light II cells as a control (CTR). 
Treatment time was 48 h, and normalization was against Renilla luciferase. Data from three independent 
experiments. Error bars indicate SD. *P, 0.05 vs CTR. 
 
 
We wished to investigate whether ATI compounds, like the structurally related ARAP derivatives,37 
could behave as inhibitors of Hh signaling. We selected three highly potent ATI derivatives, 33, 44 and 
2-(1H-imidazol-1-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (81),15 and their effects were 
evaluated by a luciferase assay performed in NIH3T3 Shh-Light II (Shh-LII) cells. In these cells, in 
which is stably incorporated an Hh-responsive (Gli-RE) reporter, the induction of the pathway occurs 
following treatment with the SMO agonist SAG. ATIs 33, 44 and 81 showed a strong reduction of 
luciferase activity in cells treated with SAG in a dose-dependent manner (Figure 10), yielding IC50’s of 
19, 72 and 38 nM, respectively. The treatment did not decrease the control Renilla luciferase activity, 
preventing any cytotoxicity mediated effects on the inhibition of Hh signaling. To address the ability of 
these compounds to affect D283 medulloblastoma cell proliferation and survival, we performed a 
trypan blue count assay. The in vitro treatment with ATI 33, 44 or 81 at 1 ȝM impaired cell growth and 
the percentage of cell death, as shown in Figure 16S, Supporting Information. 
Table 5. Metabolic Stability with Human and Mouse Liver Microsomesa and Aqueous 
Solubility of Compounds 33 and 44. 
 
 Clearance (L/min/mg protein)b,c  
 
compd 
Human liver 
microsomes 
Mouse liver 
microsomes 
Solubility 
pH 7.4d (M) 
33 15.2  8.0 43.1  7.9 0.99  0.13 
44 <3 25.6  1.7 3.18  0.50 
7-ethoxycoumarin 209  10.2 710.8  1.2 — 
propranolol 19.1  2.2 235.1  24.1 — 
aMetabolic stability: <3, good; 3−͸Ͳ, medium; >͸Ͳ, low. bResults are expressed as mean ± 
SD, n = 2. cThe standard compounds 7-ethoxycoumarin and propranolol showed 
metabolic stability in agreement with the literature and internal validation data REF. 
dHigh throughput screening solubility assay. 
 
 
Hh inhibitors are attracting ever growing attention because of benefits displayed in the treatment of 
Hh-dependent cancers, such as medulloblastomas.40 However, the problem of drug resistance to Smo 
mutations, arising during clinical treatment, has led to a quest for new Hh inhibitors. ATIs 33, 44 and 
81 showed potent inhibition of the Hh signaling pathway, suggesting that the ATI class has potential as 
Hh-dependent anticancer agents. 
Metabolic stability. Compounds 33 and 44 were examined in a microsomal stability assay in 
comparison with 7-ethoxycoumarin and propranolol as control compounds, using both human and 
mouse liver microsomes, to estimate compound stability to phase I oxidative metabolism (Table 5). 
Compound 44 showed metabolic stability of 25.6 and <3 L/min/mg protein in mouse and human liver 
microsomes, respectively. Compound 33, showed medium metabolic stability with human liver 
microsomes and low-medium metabolic stability with mouse liver microsomes (relative stabilities are 
defined in the Table 5 legend). 
Aqueous solubility. The solubility in aqueous pH 7.4 buffer of compounds 33 and 44 was measured 
in a high throughput screening solubility assay. The solubility of compound 33 was about 1 M, while 
under the same conditions, compound 44 showed a solubility of 3.2 M (Table 5). 
 
CONCLUSION 
We designed 39 new 2-phenylindole derivatives as potential anticancer agents bearing the 3,4,5-
trimethoxyphenyl moiety linked through a sulfur, ketone or methylene bridging group at position 3 of 
the indole and with halogen or methoxy substituent(s) at positions 4-7. Twenty-three new derivatives 
inhibited tubulin polymerization with IC50 values of 1.0-2.0 ȝM and inhibited colchicine binding with a 
mean value >70%; fifteen derivatives inhibited the growth of human MCF-7 cells with IC50 values ≤50 
nM. 
Compounds 33 and 44, representative members of this series, uniformly inhibited at nanomolar 
concentration a panel of cancer cells, including MDA-MB-468, MDA-MB-436, MDA MB-231, MV4-
11, NB4, A-549, NCI-H1975, T98G and U343 cells. As inhibitors of PC-3, RD, and HepG2 cancer cell 
growth, 33 and 44 were superior to the references VBL and PTX. ATI 33 and 44 were comparable to 2 
as inhibitors of the MDR NCI/ADR-RES and Messa/Dx5 cell lines. Besides the ability to inhibit 
tubulin polymerization, for which they were originally designed, ATIs 33 and 44 exhibited an 
unexpected stimulation of the cytotoxic activity of NK cells. Our findings demonstrated that 33 and 44 
at doses of 10 nM, which did not severely affect cell viability, increased NKG2D and DNAM-1 ligand 
up-regulation of HeLa cells, resulting in an enhanced stimulation of NK cell cytotoxic activity. This 
novel effect of ATIs, elicited at sublethal doses, along with a stronger expression of NK cell receptor-
activating ligand, led to an increased propensity of NK cells to degranulate against tumor cells. At 
higher concentrations of 20-50 nM, ATIs 33 and 44 induced >80% of HeLa cells to arrest with a G2/M 
DNA content, an effect similar to that observed with VBL, with very few cells progressing past the 4N 
G2/M phase. These compounds stably arrested mitotic progression, prevented mitotic slippage and the 
ensuing formation of aneuploid cells - a hallmark of aggressive cancers - and induced cell death. These 
findings suggest that the new ATIs 33 and 44 can arrest proliferation of cancer cells with effectiveness 
comparable or superior to that obtained with VBL. ATIs 44 and 81 showed strong inhibition of the Hh 
signaling pathway, inhibiting medulloblastoma D283 cells with IC50s of 72 and 38 nM, respectively. 
In summary, these novel ATI compounds show potential to treat cancer via both MT-based and 
MT-independent pathways. Even at low concentrations where the ATIs do not fully prevent the 
assembly of the mitotic apparatus, and hence mitotic cell death, these agents effectively up-regulate NK 
ligands and trigger an alternative cytotoxic response via NK cells. Here we have described the broad 
potential of the new ATIs in an in-depth characterization of the cell response to increasing drug 
concentrations. We aim to assess whether specific MT-associated proteins (MAPs) can modulate cell 
sensitivity to these drugs and favor one pathway over the other. Such MAPs may serve as effective 
biomarkers to predict the prevalent response to ATI treatment. Compounds 33 and 44 represent novel 
lead compounds that will prompt further development of the ATI class to obtain new promising 
anticancer agents with enhanced stimulation of NK cell cytotoxic activity and repression of Hh-
dependent cancers. Derivative 44 showed higher metabolic stability than 33 in human and mouse liver 
microsomes and greater water solubility. The present results highlight the therapeutic potential of the 
ATI class as anticancer agents and prompt further developmental studies. 
 
Experimental Section 
Chemistry. Microwave-assisted reactions were performed on a CEM Discover SP single mode 
reactor. The instrument settings were controlled with PC-running CEM Synergy 1.49 software. Closed 
vessel experiments were carried out in capped microwave-dedicated vials (10 mL) with cylindrical 
stirring bar (length 8 mm, diameter 3 mm). Open vessel experiments were carried out in 100 mL round-
bottom flasks equipped with a Dimroth reflux condenser and a cylindrical stirring bar (length 20 mm, 
diameter 6 mm). Stirring, temperature, irradiation power, maximum pressure (Pmax), PowerMAX 
(simultaneous cooling-while-heating), ActiVent (simultaneous venting-while-heating), and ramp and 
hold times were set as indicated. Temperature of the reaction was monitored by an external fiber optic 
temperature sensor. After completion of the reaction, the mixture was cooled to 25 °C via air-jet 
cooling. Melting points (mp) were determined on a Stuart Scientific SMP1 apparatus and are 
uncorrected. Infrared (IR) spectra were run on a Perkin-Elmer SpectrumOne FT-ATR 
spectrophotometer. Band position and absorption ranges are given in cm-1. Proton nuclear magnetic 
resonance (1H NMR) spectra were acquired on a Bruker 400 MHz FT spectrometer in the indicated 
solvent by TopSpin 2.1 software and the files processed by MestreLab Research S.L. MestreReNova 
6.2.1-769 software. Chemical shifts are expressed in δ units (ppm) from tetramethylsilane. 
Multiplicities are indicated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br 
(broadened), broad s (broadened singlet), and coupling constants (J) are reported in Hertz (Hz). Flash 
chromatography was carried out on Interchim Spot II Flash, using Merck SuperVarioFlash D26 
cartridges packed with Merck Geduran 60 (0.040-0.063 mm) silica gel. Column chromatography was 
performed on columns packed with alumina from Merck (70-230 mesh) or silica gel from Macherey-
Nagel (70-230 mesh). Aluminum oxide thin layer chromatography (TLC) cards from Fluka (aluminum 
oxide precoated aluminum cards with fluorescent indicator visualizable at 254 nm) and silica gel TLC 
cards from Macherey-Nagel (silica gel precoated aluminum cards with fluorescent indicator 
visualizable at 254 nm) were used for TLC. Developed plates were visualized by a Spectroline ENF 
260C/FE UV apparatus. Organic solutions were dried over anhydrous sodium sulfate. Evaporation of 
solvents was carried out on a Büchi Rotavapor R-210 equipped with a Büchi V-850 vacuum controller 
and a Büchi V-700 or V-710 vacuum pump. All commercially available reagents were used without 
further purification. Elemental analyses of the compounds were found within ± 0.4% of the theoretical 
values. Purity of tested compounds was determined by high pressure liquid chromatography (HPLC) 
and was >95%. The HPLC system (Dionex UltiMate 3000, Thermo Fisher Scientific Inc.) was 
equipped with a SR-3000 solvent rack, a LPG-3400SD quaternary analytical pump, a TCC-3000SD 
column compartment, a DAD-3000 diode array detector and an analytical manual injection valve with 
a 20 µL loop. Compounds were dissolved in acetonitrile (10 mg/mL). HPLC analysis was performed 
by using an Acclaim 120 C18 reversed-phase column (5 µm, 4.6 x 250 mm, Thermo Fisher Scientific 
Inc.) at a temperature of 30 ± 1 °C, an isocratic gradient (acetonitrile:water = 90:10), a flow rate of 1.0 
mL/min and a detector signal of 254 and 365 nm. Chromatographic data were acquired and processed 
by Chromeleon 6.80 software (Thermo Fisher Scientific Inc.). 
1. Synthesis of Compounds 6-45. General Procedure for the Preparation of 6, 8, 11, 13, 15, 18, 
21, 23, 26, 28, 31, 33, 35, 37, 40, 42 and 44. Example. 4-Bromo-2-phenyl-3-((3,4,5-
trimethoxyphenyl)thio)-1H-indole (6). A mixture of 4-bromo-2-phenyl-1H-indole (46) (0.27 g, 1 mmol), 
bis-(3,4,5-trimethoxyphenyl)disulfide (0.44 g, 1.1 mmol), and sodium hydride (0.053 g, 2.2 mmol; 
60% in mineral oil) in anhydrous DMF (3 mL) was placed into the microwave cavity (closed vessel 
mode, Pmax = 250 psi). Starting microwave irradiation of 120 W was used, the temperature being 
ramped from 25 to 130 °C, while rapidly stirring and venting (pressure set point: 100 psi; times at set 
point: 100; delta pressure: 20 psi). Once 130 °C was reached, taking about 1 min, the reaction mixture 
was held at this temperature for 2 min. The mixture was diluted with water and extracted with ethyl 
acetate. The organic layer was washed with brine and dried. Removal of the solvent gave a residue that 
was purified by flash chromatography (silica gel, ethyl acetate/n-hexane as eluent) to furnish 6 (0.13 g, 
27%), mp 202-205 °C (from ethanol). 1H NMR (CDCl3):  3.66 (s, 6H), 3.79 (s, 3H), 6.37 (s, 2H), 7.10 
(t, J = 7.8 Hz, 1H), 7.38-7.41 (m, 5H), 7.71 (d, J = 6.7 Hz, 2H), 8.72 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  3344 cm-1. Anal. (C23H20BrNO3S (470.38)) C, H, Br, N, S. 
4-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (8). Synthesized as 6, starting from 
4-chloro-2-phenyl-1H-indole (47). Yield 62%, mp 178-180 °C (from ethanol). 1H NMR (DMSO-d6):  
3.54 (s, 6H), 3.57 (s, 3H), 6.26 s, 2H), 7.10-7.11 (m, 1H), 7.18-7.20 (m, 1H), 7.44-7.54 (m, 4H), 7.77-
7.80 (m, 2H), 12.51 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3345 cm-1. Anal. 
(C23H20ClNO3S (425.93)) C, H, Cl, N, S. 
4-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (11). Synthesized as 6, starting from 
4-fluoro-2-phenyl-1H-indole (48). Yield 30%, mp 168-170 °C (from ethanol). 1H NMR (DMSO-d6):  
3.53 (s, 6H), 3.56 (s, 3H), 6.28 (s, 2H), 6.80-6.85 (m, 1H), 7.14-7.19 (m, 1H), 7.32 (d, J = 8.0 Hz, 1H), 
7.44 (t, J = 7.1 Hz, 1H), 7.51 (t, J = 7.1 Hz, 2H), 7.80-7.82 (m, 2H), 12.30 ppm (broad s, disappeared 
on treatment with D2O, 1H). IR:  3307 cm-1. Anal. (C23H20FNO3S (409.47)) C, H, F, N, S. 
4-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (13). Synthesized as 6, starting 
from 4-methoxy-2-phenyl-1H-indole (49). Yield 41%, mp 133-136 °C (from toluene). 1H NMR 
(CDCl3):  3.66 (s, 6H), 3.78 (s, 6H), 6.44 (s, 2H), 6.57-6.59 (m, 1H), 7.05 (d, J = 8.2 Hz, 1H), 7.18 (t, 
J = 7.7 Hz, 1H), 7.38-7.48 (m, 3H), 7.73 (d, J = 7.2 Hz, 2H), 8.52 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  3261 cm-1. Anal. (C24H23NO4S (421.51)) C, H, N, S. 
5-Bromo-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (15). Synthesized as 6, starting from 
5-bromo-2-phenyl-1H-indole (50). Yield 18%, mp 152-155 °C (from ethanol). 1H NMR (DMSO-d6):  
3.53 (s, 6H), 3.56 (s, 3H), 6.27 (s, 2H), 7.32-7.35 (m, 1H), 7.44-7.58 (m, 5H), 7.86-7.88 (m, 2H), 12.29 
ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3316 cm-1. Anal. (C23H20BrNO3S 
(470.38)) C, H, Br, N, S.  
5-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (18). Synthesized as 6, starting from 
5-chloro-2-phenyl-1H-indole (51). Yield 20%, mp 158-160 °C (from ethanol). 1H NMR (CDCl3):  
3.65 (s, 6H), 3.78 (s, 3H), 6.33 (s, 2H), 7.21-7.24 (m, 1H), 7.36-7.49 (m, 4H), 7.66-7.67 (m, 1H), 7.77-
7.80 (m, 2H), 8.69 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3319 cm-1. Anal. 
(C23H20ClNO3S (425.93)) C, H, Cl, N, S. 
5-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (21). Synthesized as 6, starting from 
5-fluoro-2-phenyl-1H-indole (52). Yield 26%, mp 158-160 °C (from toluene). 1H NMR (DMSO-d6):  
3.54 (s, 6H), 3.57 (s, 3H), 6.30 (s, 2H), 7.1 (t, J = 8.0 Hz, 1H), 7.16 (d, J = 9.2 Hz, 1H), 5.45 (t, J = 7.2 
Hz, 1H), 7.50-7.55 (m, 3H), 7.88 (d, J = 7.4 Hz, 2H), 12.21 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR:  3231 cm-1. Anal. (C23H20FNO3S (409.47)) C, H, F, N, S. 
5-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (23). Synthesized as 6, starting 
from 5-methoxy-2-phenyl-1H-indole (53). Yield 20% as an oil. 1H NMR (CDCl3):  3.63 (s, 6H), 3.77 
(s, 3H), 3.83 (s, 3H), 6.35 (s, 2H), 6.90-6.93 (m, 1H), 7.10-7.11 (m, 1H), 7.32-7.46 (m, 4H), 7.76-7.77 
(m, 2H), 8.58 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3337 cm-1. Anal. 
(C24H23NO4S (421.51)) C, H, N, S. 
6-Bromo-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (26). Synthesized as 6, starting from 
6-bromo-2-phenyl-1H-indole (54). Yield 22%, mp 200-203 °C (from ethanol). 1H NMR (DMSO-d6):  
3.57 (s, 3H), 3.58 (s, 6H), 6.78 (s, 2H), 7.23-7.27 (m, 3H), 7.35-7.41 (m, 3H), 7.48 (d, J = 8.3 Hz, 1H), 
8.09 (s, 1H), 12.40 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3320 cm-1. Anal. 
(C23H20BrNO3S (470.38)) C, H, Br, N, S. 
6-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (28). Synthesized as 6, starting from 
6-chloro-2-phenyl-1H-indole (55). Yield 25%, mp 207-210 °C (from ethanol). 1H NMR (DMSO-d6):  
3.54 (s, 6H), 3.57 (s, 3H), 6.29 (s, 2H), 7.14 (dd, J = 1.1 and 7.7 Hz, 1H), 7.43-7.55 (m, 5H), 7.87 (d, J 
= 7.9 Hz, 2H), 12.23 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3319 cm-1. Anal. 
(C23H20ClNO3S (425.93)) C, H, Cl, N, S. 
6-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (31). Synthesized as 6, starting from 
6-fluoro-2-phenyl-1H-indole (56). Yield 37% as an oil. 1H NMR (CDCl3):  3.64 (s, 6H), 3.78 (s, 3H), 
6.35 (s, 2H), 6.96 (t, J = 8.8 Hz, 1H), 7.14 (d, J = 9.0 Hz, 1H), 7.41-7.50 (m, 3H), 7.58-7.59 (m, 1H), 
7.78 (d, J = 8.0 Hz, 2H), 8.56 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3320 cm-1. 
Anal. (C23H20FNO3S (409.47)) C, H, F, N, S. 
6-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (33). Synthesized as 6, starting 
from 6-methoxy-2-phenyl-1H-indole (57). Yield 24%, mp 121-124 °C (from toluene). 1H NMR 
(DMSO-d6):  3.54 (s, 6H), 3.60 (s, 3H), 3.81 (s, 3H), 6.31 (s, 2H), 6.77 (dd, J = 2.2 and 8.6 Hz, 1H), 
6.97 (d, J = 2.0 Hz, 1H), 7.34-7.42 (m, 2H), 7.50 (t, J = 7.4 Hz, 2H), 7.85 (d, J = 7.2 Hz, 2H), 11.88 
ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3322 cm-1. Anal. (C24H23NO4S (421.51)) 
C, H, N, S. 
7-Bromo-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (35). Synthesized as 6, starting from 
7-bromo-2-phenyl-1H-indole (58). Yield 39%, mp 142-145 °C (from toluene). 1H NMR (DMSO-d6):  
3.54 (s, 6H), 3.57 (s, 3H), 6.29 (s, 2H), 7.08 (t, J = 7.7Hz, 1H), 6.97 (d, J = 7.7 Hz, 1H), 7.43-7.54 (m, 
5H), 7.82 (d, J = 7.1 Hz, 1H), 12.11 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3335 
cm-1. Anal. (C23H20BrNO3S (470.38)) C, H, Br, N, S. 
7-Chloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (37). Synthesized as 6, starting from 
7-chloro-2-phenyl-1H-indole (59). Yield 77%, mp 62-65 °C (from ethanol). 1H NMR (CDCl3):  3.66 
(s, 6H), 3.78 (s, 3H), 6.36 (s, 2H), 7.12-7.17 (m, 1H), 7.43-7.57 (m, 4H), 7.58-7.60 (m, 1H), 7.83-7.85 
(m, 2H), 8.72 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3259 cm-1. Anal. 
(C23H20ClNO3S (425.93)) C, H, Cl, N, S. 
7-Fluoro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (40). Synthesized as 6, starting from 
7-fluoro-2-phenyl-1H-indole (60). Yield 32%, mp 98-100 °C (from toluene). 1H NMR (DMSO-d6):  
3.54 (s, 6H), 3.57 (s, 3H), 6.30 (s, 2H), 7.05-7.10 (m, 2H), 7.31 (d, J = 7.1 Hz, 1H), 7.46 (t, J = 7.2 Hz, 
1H), 7.53 (t, J = 7.1 Hz, 2H), 7.88 (d, J = 7.2 Hz, 2H), 12.46 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR:  3247 cm-1. Anal. (C23H20FNO3S (409.47)) C, H, F, N, S. 
7-Methoxy-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (42). Synthesized as 6, starting 
from 7-methoxy-2-phenyl-1H-indole (61). Yield 57%, mp 158-160 °C (from ethanol). 1H NMR 
(DMSO-d6):  3.53 (s, 6H), 3.57 (s, 3H), 3.97 (s, 3H), 6.29 (s, 2H), 6.79-6.81 (m, 1H), 7.04-7.08 (m, 
2H), 7.40-7.49 (m, 3H), 7.83-7.86 (m, 2H), 12.09 ppm (broad s, disappeared on treatment with D2O, 
1H). IR:  3300 cm-1. Anal. (C24H23NO4S (417.45)) C, H, N, S. 
6,7-Dichloro-2-phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (44). Synthesized as 6, starting 
from 6,7-dichloro-2-phenyl-1H-indole (62). Yield 57%, mp 158-160 °C (from ethanol). 1H NMR 
(DMSO-d6):  3.55 (s, 6H), 3.57 (s, 3H), 6.29 (s, 2H), 7.32 (d, J = 8.5 Hz, 1H), 7.44-7.55 (m, 4H), 
7.83-7.85 (m, 2H), 12.44 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1610, 3268 cm-1. 
Anal. (C23H19Cl2NO3S (460.37)) C, H, Cl, N, S. 
General Procedure for the Preparation of 7, 9, 12, 14, 16, 19, 22, 24, 27, 29, 32, 34, 36, 38, 41, 
43 and 45. Example. (4-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (7). A 
mixture of 46 (0.27 g, 1 mmol), 3,4,5-trimethoxybenzoyl chloride (0.23 g, 1 mmol), and anhydrous 
aluminum chloride (0.13 g, 1 mmol) in anhydrous 1,2-dichloroethane (2 mL) was placed into the 
microwave cavity (closed vessel mode, Pmax = 250 psi). A starting microwave irradiation of 150 W 
was used, the temperature being ramped from 25 °C to 110 °C while stirring. Once 110 °C was reached, 
taking about 1 min, the reaction mixture was held at this temperature for 2 min. The reaction mixture 
was quenched on 1 M HCl/crushed ice and extracted with chloroform. The organic layer was washed 
with brine, dried, and filtered. Removal of the solvent gave a residue that was purified by flash 
chromatography (silica gel, ethyl acetate/n-hexane as eluent) to furnish 7 (0.09 g, 20%), mp 228-
230 °C (from ethanol). 1H NMR (CDCl3):  3.74 (s, 6H), 3.88 (s, 3H), 7.13-7.16 (m, 3H), 7.31-7.37 (m, 
4H), 7.42-7.46 (m, 3H), 8.58 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1618, 3344 
cm-1. Anal. (C24H20BrNO4 (466.32)) C, H, Br, N. 
(4-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (9). Synthesized as 7, 
starting from 47. Yield 35%, mp 232-235 °C (from ethanol). 1H NMR (CDCl3):  3.72 (s, 6H), 3.94 (s, 
3H), 7.17 (s, 2H), 7.19-7.23 (m, 2H), 7.30-7.33 (m, 3H), 7.38 (dd, J = 2.0 and 7.0 Hz, 1H), 7.45-7.48 
(m, 2H), 8.73 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1618, 3169 cm-1. Anal. 
(C24H20ClNO4 (421.87)) C, H, Cl, N. 
(4-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (12). Synthesized as 7, 
starting from 48. Yield 25%, mp 212-215 °C (from toluene). 1H NMR (DMSO-d6):  3.62 (s, 6H), 3.64 
(s, 3H), 6.84-6.89 (m, 1H), 6.99 (s, 2H), 7.18-7.22 (m, 1H), 7.30-7.35 (m, 4H), 7.42-7.44 (m, 2H), 
12.34 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1618, 3205 cm-1. Anal. 
(C24H20FNO4 (405.42)) C, H, F, N. 
(4-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (14). Synthesized as 7, 
starting from 49. Yield 51%, mp 144-146 °C (from toluene). 1H NMR (DMSO-d6):  3.53 (s, 3H), 3.64 
(s, 6H), 3.69 (s, 3H), 6.55-6.57 (m, 1H), 7.02 (s, 2H), 7.09-7.16 (m, 2H), 7.29-7.39 (m, 3H), 7.49-7.51 
(m, 2H), 11.95 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1622, 3220 cm-1. Anal. 
(C25H23NO5 (417.45)) C, H, N. 
 (5-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (16). Synthesized as 7, 
starting from 50. Yield 55%, mp 200-203 °C (from ethanol). 1H NMR (DMSO-d6):  3.57 (s, 3H), 3.58 
(s, 6H), 6.78 (s, 2H), 7.23-7.27 (m, 3H), 7.35-7.41 (m, 3H), 7.48 (d, J = 8.3 Hz, 1H), 8.09 (s, 1H), 
12.40 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1610, 3305 cm-1. Anal. 
(C24H20BrNO4 (466.32)) C, H, Br, N. 
 (5-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (19). Synthesized as 7, 
starting from 51. Yield 54%, mp 222-225 °C (from ethanol). 1H NMR (CDCl3):  3.69 (s, 6H), 3.81 (s, 
3H), 6.94 (s, 2H), 7.24-7.30 (m, 4H), 7.33-7.40 (m, 3H), 8.07-8.08 (m, 1H), 8.81 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  1610, 3340 cm-1. Anal. (C24H20ClNO4 (421.87)) C, H, 
Cl, N. 
(5-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (22). Synthesized as 7, 
starting from 52. Yield 66%, mp 198-200 °C (from toluene). 1H NMR (DMSO-d6):  3.58 (s, 3H), 3.59 
(s, 6H), 6.78 (s, 2H), 7.10-7.15 (m, 1H), 7.24-7.27 (m, 3H), 7.34-7.37 (m, 2H), 7.51 (q, J = 4.6 Hz, 1H), 
7.66 (dd, J = 2.5 and 10.1, 1H), 12.30 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  
1620, 3225 cm-1. Anal. (C24H20FNO4 (405.42)) C, H, F, N. 
(5-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (24). Synthesized as 7 
starting from 53. Yield 78%, mp 202-205 °C (from ethanol). 1H NMR (DMSO-d6):  3.58 (s, 3H), 3.59 
(s, 6H), 3.78 (s, 3H), 6.78 (s, 2H), 6.90 (dd, J = 2.6 and 8.8 Hz, 1H), 7.24-7.25 (m, 3H), 7.32-7.34 (m, 
2H), 7.41 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 2.4 Hz, 1H), 12.11 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR:  1652, 3195 cm-1. Anal. (C25H23NO5 (417.45)) C, H, N. 
(6-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (27). Synthesized as 7, 
starting from 54. Yield 40% as an oil. 1H NMR (CDCl3):  3.68 (s, 6H), 3.81 (s, 3H), 6.94 (s, 2H), 
7.23-7.27 (m, 3H), 7.33-7.36 (m, 3H), 7.59 (s, 1H), 7.87 (d, J = 8.6 Hz, 1H), 8.84 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  1610, 3304 cm-1. Anal. (C24H20BrNO4 (466.32)) C, H, 
Br, N. 
 (6-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (29). Synthesized as 7, 
starting from 55. Yield 67%, mp 188-190 °C (from ethanol). 1H NMR (CDCl3):  3.63 (s, 6H), 3.79 (s, 
3H), 6.93 (s, 2H), 7.20-7.24 (m, 4H), 7.31-7.33 (m, 2H), 7.41-7.43 (m, 1H), 7.91 (d, J = 8.6 Hz, 1H), 
8.84 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3319, 1618 cm-1. Anal. 
(C24H20ClNO4 (421.87)) C, H, Cl, N. 
(6-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (32). Synthesized as 7, 
starting from 56. Yield 25% as an oil. 1H NMR (CDCl3):  3.68 (s, 6H), 3.80 (s, 3H), 6.94 (s, 2H), 7.05 
(t, J = 8.9 Hz, 1H), 7.14 (d, J = 9.0 Hz, 1H), 7.26-7.33 (m, 5H), 7.99-8.02 (m, 1H), 8.58 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  1621, 3265 cm-1. Anal. (C24H20FNO4 (405.42)) C, H, F, 
N. 
 (6-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (34). Synthesized as 7, 
starting from 57. Yield 63%, mp 186-188 °C (from toluene). 1H NMR (DMSO-d6):  3.59 (s, 9H), 3.83 
(s, 3H), 6.80 (s, 2H), 6.85 (dd, J = 2.3 and 8.8 Hz, 1H), 6.97 (d, J = 2.2 Hz, 1H), 7.24-7.26 (m, 3H), 
7.32-7.34 (m, 2H), 7.79 (d, J = 8.8 Hz, 1H), 12.01 ppm (broad s, disappeared on treatment with D2O, 
1H). IR:  1610, 3302 cm-1. Anal. (C25H23NO5 (417.45)) C, H, N. 
(7-Bromo-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (36). Synthesized as 7, 
starting from 58. Yield 58%, mp 188-190 °C (from ethanol). 1H NMR (CDCl3):  3.71 (s, 6H), 3.82 (s, 
3H), 6.97 (s, 2H), 7.18 (t, J = 7.8 Hz, 1H), 7.28-7.32 (m, 3H), 7.42-7.44 (m, 2H), 7.48 (d, J = 7.6 Hz, 
1H), 7.99 (d, J = 8.0 Hz, 1H), 8.67 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1618, 
3258 cm-1. Anal. (C24H20BrNO4 (466.32)) C, H, Br, N. 
(7-Chloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (38). Synthesized as 7, 
starting from 59. Yield 64%, mp 148-150 °C (from ethanol). 1H NMR (DMSO-d6):  3.59 (s, 3H), 3.61 
(s, 6H), 6.80 (s, 2H), 7.20-7.29 (m, 4H), 7.34 (dd, J = 1.0 and 7.6 Hz, 1H), 7.38-7.41 (m, 2H), 7.88 (dd, 
J = 1.0 and 8.0 Hz, 1H), 12.41 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1607, 
3215 cm-1. Anal. (C24H20ClNO4 (421.87)) C, H, Cl, N. 
 (7-Fluoro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (41). Synthesized as 7, 
starting from 60. Yield 65%, mp 172-175 °C (from toluene). 1H NMR (DMSO-d6):  3.59 (s, 3H), 3.61 
(s, 6H), 6.81 (s, 2H), 7.07-7.18 (m, 2H), 7.26-7.27 (m, 3H), 7.38-7.40 (m, 2H), 7.72 (d, J = 7.8 Hz, 1H), 
12.60 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1615, 3254 cm-1. Anal. 
(C24H20FNO4 (405.42)) C, H, F, N. 
(7-Methoxy-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (43). Synthesized as 7, 
starting from 61. Yield 20%, mp 185-188 °C (from ethanol). 1H NMR (DMSO-d6):  3.59 (s, 3H), 3.60 
(s, 6H), 3.98 (s, 3H), 6.79 (s, 2H), 6.83 (d, J = 7.4 Hz, 1H), 7.11 (t, J = 7.9 Hz, 1H), 7.20-7.23 (m, 3H), 
7.35-7.38 (m, 2H), 7.47-7.49 (m,1H), 12.24 ppm (broad s, disappeared on treatment with D2O, 1H). IR: 
 1606, 3270 cm-1. Anal. (C25H23NO5 (417.45)) C, H, N. 
 (6,7-Dichloro-2-phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (45). Synthesized as 7, 
starting from 62. Yield 23%, mp 218-220 °C (from ethanol). 1H NMR (DMSO-d6):  3.59 (s, 3H), 3.61 
(s, 6H), 6.81 (s, 2H), 7.25-7.32 (m, 3H), 7.39-7.42 (m, 3H), 7.86 (d, J = 8.5 Hz, 1H), 12.58 ppm (broad 
s, disappeared on treatment with D2O, 1H). IR:  1607, 3271 cm-1. Anal. (C24H19Cl2NO4S (456.32)) C, 
H, Cl, N, S. 
General Procedure for the Preparation of 10, 20, 25, 30 and 39. Example. 4-Chloro-2-phenyl-3-
(3,4,5-trimethoxybenzyl)-1H-indole (10). Borane tetrahydrofuran complex (1.0 mL, 1.0 M in 
tetrahydrofuran) was slowly added to a cold solution of 9 (0.1 g, 0.24 mmol) in anhydrous acetonitrile 
(1.4 mL) containing anhydrous methanol (0.02 mL) under an Ar stream. The reaction was stirred at 
50 °C for 1 h. After cooling, the mixture was carefully diluted with water and extracted with ethyl 
acetate. The organic layer was washed with brine, dried and filtered. Removal of the solvent gave a 
residue that was purified by flash chromatography (silica gel, ethyl acetate/n-hexane as eluent) to 
furnish 10 (0.01 g, 10%), mp 178-180 °C (from ethanol). 1H NMR (CDCl3):  3.74 (s, 6H), 3.84 (s, 
3H), 4.45 (s, 2H), 6.44 (s, 2H), 7.10-7.15 (m, 2H), 7.33 (dd, J = 2.2 and 6.8 Hz, 1H), 7.41-7-47 (m, 3H), 
7.51-7.53 (m, 2H), 8.29 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3358 cm-1. Anal. 
(C24H22ClNO3 (407.89)) C, H, Cl, N. 
5-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (20). Synthesized as 10, starting from 19. 
Yield 41%, mp 172-175 °C (from ethanol). 1H NMR (CDCl3):  3.76 (s, 6H), 3.82 (s, 3H), 4.16 (s, 2H), 
6.41 (s, 2H), 7.15 (dd, J = 2.0 and 8.6 Hz, 1H), 7.31 (d, J = 8.6 Hz, 1H), 7.37-7.39 (m, 1H), 7.42-7.46 
(m, 3H), 7.51-7.54 (m, 2H), 8.23 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3340 
cm-1. Anal. (C24H22ClNO3 (407.89)) C, H, Cl, N. 
5-Methoxy-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (25). Synthesized as 10, starting from 24. 
Yield 26%, mp 137-139 °C (from ethanol). 1H NMR (DMSO-d6):  3.59 (s, 3H), 3.60 (s, 6H), 3.72 (s, 
3H), 4.14 (s, 2H), 6.48 (s, 2H), 6.76 (dd, J = 2.4 and 8.9 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 7.27 (d, J = 
8.9 Hz, 1H), 7.35-7.39 (m, 1H), 7.50 (t, J = 7.4 Hz, 2H), 7.61-7.64 (m, 2H), 11.12 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  3361 cm-1. Anal. (C25H25NO4 (403.47)) C, H, N. 
6-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (30). Synthesized as 10, starting from 29. 
Yield 41%, mp 187-185 °C (from ethanol). 1H NMR (CDCl3):  3.73 (s, 6H), 3.84 (s, 3H), 4.21 (s, 2H), 
6.44 (s, 2H), 7.07 (dd, J = 2.0 and 8.4 Hz, 1H), 7.38-7.42 (m, 3H), 7.45-7.49 (m, 2H), 7.53-7.56 (m, 
2H), 8.25 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3332 cm-1. Anal. (C24H22ClNO3 
(407.89)) C, H, Cl, N. 
7-Chloro-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (39). Synthesized as 10, starting from 38. 
Yield 41%, mp 156-158 °C (from ethanol). 1H NMR (CDCl3):  3.74 (s, 6H), 3.83 (s, 3H), 4.22 (s, 2H), 
6.44 (s, 2H), 7.05 (t, J = 7.8 Hz, 1H), 7.22-7-24 (m, 1H), 7-39-7.45 (m, 2H), 7.48-7.51 (m, 2H), 7.59-
7.61 (m, 2H), 8.34 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3347 cm-1. Anal. 
(C24H22ClNO3 (407.89)) C, H, Cl, N. 
5-Bromo-2-phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (17). A mixture of 16 (0.25 g, 0.54 mmol), 
triethylsilane (0.14 g, 0.19 mL, 1.2 mmol) and trifluoroacetic acid (0.63 g, 0.41 mL, 5.5 mmol) in 1,2-
dichloroethane (2.0 mL) was placed into the microwave cavity (closed vessel mode, Pmax = 250 psi). 
A starting microwave irradiation of 250 W was used, the temperature being ramped from 25 to 250 °C 
while rapidly stirring and cooling. Once 250 °C was reached, taking about 2 min, the reaction mixture 
was held at this temperature for 20 min. The reaction mixture was diluted with a saturated aqueous 
solution of NaHCO3 and extracted with ethyl acetate. The organic layer was washed with brine, dried, 
and filtered. Removal of the solvent gave a residue that was purified by flash chromatography (silica 
gel, ethyl acetate/n-hexane as eluent) to furnish 17 (0.04 g, 15%) as a colorless oil. 1H NMR (CDCl3):  
3.73 (s, 6H), 3.83 (s, 3H), 4.17 (s, 2H), 6.42 (s, 2H), 7.28 (s, 2H), 7.37-7.47 (m, 3H), 7.53-7.55 (m, 2H), 
7.62 (s, 1H), 8.25 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3338 cm-1. Anal. 
(C24H22BrNO3 (452.34)) C, H, Br, N. 
2. Synthesis of Compounds 46-62. General Procedure for the Preparation of 46, 54 and 56. 
Example. 4-Bromo-2-phenyl-1H-indole (46). A mixture of 66 (0.1 g, 0.4 mmol), tin(II) chloride 
dihydrate (1.35 g, 6 mmol) and 1 N HCl (0.92 mL) in glacial acetic acid (4.80 mL) was heated at reflux 
temperature for 12 h. After cooling, the reaction mixture was diluted with a saturated aqueous solution 
of potassium carbonate and extracted with ethyl acetate. The organic layer was washed with brine, 
dried and filtered. Removal of the solvent gave a residue that was purified by column chromatography 
(silica gel, chloroform as eluent) to furnish 46 (0.02 g, 19%), mp 98-100 °C, Lit.41 mp 100-102 °C. 
6-Bromo-2-phenyl-1H-indole (54). Synthesized as 46, starting from 67. Yield 46%, mp 188-190 °C 
(from ethanol), Lit.42 187 °C. 
6-Fluoro-2-phenyl-1H-indole (56). Synthesized as 46, starting from 68. Yield 24%, mp 170-171 °C 
(from ethanol), Lit.43 171-172 °C. 
General Procedure for the Preparation of 47-49, 55, 57 and 61. Example. 4-Chloro-2-phenyl-1H-
indole (47). A solution of 69 (2.0 g, 8 mmol) in anhydrous tetrahydrofuran (120 mL) was cooled at -
40 °C, and then a solution of tert-butyllithium (9.4 mL, 16 mmol, 7.7 M in pentane) was added 
dropwise under an Ar stream. The reaction mixture was stirred at 0 °C for 1 h and at 25 °C for 12 h, 
diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and 
filtered. Removal of the solvent gave a residue that was purified by column chromatography (silica gel, 
dichloromethane as eluent) to furnish 47 (0.56 g, 31%), mp 73-76 °C (from ethanol), Lit.41 73-75 °C.  
4-Fluoro-2-phenyl-1H-indole (48). Synthesized as 47 starting from 70. Yield 52%, mp 60-62 °C 
(from ethanol), Lit. 41 62-64 °C. 
4-Methoxy-2-phenyl-1H-indole (49). Synthesized as 47, starting 71. Yield 34%, mp 100-103 °C 
(from ethanol), Lit.44 103-105 °C. 
6-Chloro-2-phenyl-1H-indole (55). Synthesized as 47, starting from 72. Yield 18%, mp 176-177 °C 
(from ethanol), Lit.45 180-181 °C. 
6-Methoxy-2-phenyl-1H-indole (57). Synthesized as 47, starting from 73. Yield 31%, mp 170-
173 °C (from ethanol), Lit.46 173-176 °C.  
7-Methoxy-2-phenyl-1H-indole (61). Synthesized as 47, starting from 74. Yield 28%, mp 83-87 °C 
(from ethanol), Lit.47 85-86 °C. 
General Procedure for the Preparation of 50-52, 58, 60 and 62. Example. 5-Bromo-2-phenyl-1H-
indole (50). Compound 75 (0.80 g, 2.8 mmol) was added by portions to polyphosphoric acid (8.0 g) 
preheated at 110 °C. The reaction mixture was stirred at the same temperature for 1 h and then 
quenched on crushed ice. The solid was filtered and crystallized from ethanol to give 75 (0.65 g, 82%), 
mp 190-192 °C, Lit.48 193-196 °C. 
5-Chloro-2-phenyl-1H-indole (51). Synthesized as 50, starting from 76. Yield 37%, mp 198-200 °C 
(from ethanol), Lit.49 203-204 °C. 
5-Fluoro-2-phenyl-1H-indole (52). Synthesized as 50, starting from 77. Yield 37%, mp 180-185 °C 
(from ethanol), Lit.50 181-183 °C. 
7-Bromo-2-phenyl-1H-indole (58). Synthesized as 50, starting from 78. Yield 14%, mp 115-117 °C 
(from ethanol), Lit.51 117-118 °C. 1H NMR (DMSO-d6):  6.97 (t, J = 7.7, 1H), 7.02 (s, 1H), 7.31-7.38 
(m, 2H), 7.47 (t, J = 7.5 HZ, 2H), 7.56 (d, J = 7.8 Hz, 1H), 7.98-8.00 (m, 2H), 11.36 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  3436 cm-1. 
7-Fluoro-2-phenyl-1H-indole (60). Synthesized as 50, starting from 79. Yield 25%, mp 122-125 °C 
(from ethanol). 1H NMR (DMSO-d6):  6.91-7.00 (m, 3H), 7.33-7.38 (m, 2H), 7.47 (t, J = 7.5 Hz, 2H), 
7.95 (d, J = 7.4 Hz, 2H), 11.85 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3436 cm-1. 
6,7-Dichloro-2-phenyl-1H-indole (62). Synthesized as 50, starting from 80. Yield 27%, mp 105-
108 °C (from ethanol). 1H NMR (DMSO-d6):  7.03 (s, 1H), 7.21 (t, J = 8.4 Hz, 1H), 7.37 (t, J = 7.4 
Hz, 1H), 7.46-7.55 (m, 3H), 7.99 (d, J = 8.0 Hz, 2H), 11.71 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR:  3248 cm-1. 
5-Methoxy-2-phenyl-1H-indole (53) was synthesized according to a Lit.52 procedure.   
7-Chloro-2-phenyl-1H-indole (59) was synthesized according to a Lit.53 procedure.  
3. Synthesis of Compounds 63-80. General Procedure for the Preparation of 63-65. Example. 
2-(2-Bromo-6-nitrophenyl)-1-phenylethanol (63). To a solution of benzaldehyde (0.12 g, 0.1 mL, 1.1 
mmol) and 2-bromo-6-nitrotoluene (0.25 g, 1.2 mmol) in anhydrous DMSO was added a solution of 
sodium ethoxide in anhydrous ethanol (0.32 mL, 0.43 M). The reaction mixture was stirred at 25 °C for 
12 h, carefully diluted with water and extracted with ethyl acetate. The organic layer was washed with 
brine, dried and filtered. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:n-hexane = 1:3 as eluent) to furnish 63 (0.15 g, 40%) as an oil. 
1H NMR (DMSO-d6):  3.21-3.24 (m, 2H), 4.64 (d, J = 7.4 Hz, 1H), 5.48 (broad s, disappeared on 
treatment with D2O, 1H), 7.25-7.33 (m, 5H), 7.42 (t, J = 8.0 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.97 
ppm (d, J = 8.2 Hz, 1H). IR:  2961, 3030, 3063, 3325, 3560 cm-1. 
2-(4-Bromo-2-nitrophenyl)-1-phenylethanol (64). Synthesized as 63, starting from 4-bromo-1-
methyl-2-nitrobenzene. Yield 44% as an oil. 1H NMR (DMSO-d6):  3.07-3.12 (m, 2H), 4.69-4.73 (m, 
1H), 5.43 (d, J = 4.5 Hz, disappeared on treatment with D2O, 1H), 7.21-7.25 (m, 1H), 7.28-7.33 (m, 
4H), 7.39 (d, J = 8.3 Hz, 1H), 7.80 (dd, J = 1.7 and 8.2 Hz, 1H), 8.08-8.10 ppm (m, 1H). IR:  2934, 
3030, 3065, 3418 cm-1. 
2-(4-Fluoro-2-nitrophenyl)-1-phenylethanol (65). Synthesized as 63, starting from 4-fluoro-1-
methyl-2-nitrobenzene. Yield 44% as an oil. 1H NMR (DMSO-d6):  3.12-3.14 (m, 2H), 4.68-4.73 (m, 
1H), 5.40 (d, J = 4.4 Hz, disappeared on treatment with D2O, 1H), 7.22-7.33 (m, 5H), 7.46-7.51 (m, 
2H), 7.81 ppm (dd, J = 2.3 and 9.0 Hz, 1H). IR:  2932, 3032, 3087, 3404 cm-1. 
General Procedure for the Preparation of 66-68. Example. 2-(2-Bromo-6-nitrophenyl)-1-
phenylethanone (66). A solution of 63 (0.1 g, 0.3 mmol) in anhydrous dichloromethane (1.0 mL) was 
added to a suspension of pyridinium chlorochromate (0.10 g, 0.47 mmol) in the same solvent (2.0 mL). 
The reaction mixture was stirred at 25 °C for 1.5 h and diluted with water. The layers were separated, 
and the organic phase was washed with brine, dried and filtered. Removal of the solvent gave a residue 
that was purified by column chromatography (silica gel, chloroform:petroleum ether = 1:1 as eluent) to 
furnish 66 (0.06 g, 40%), mp 113-115 °C (from ethanol). 1H NMR (DMSO-d6):  4.89 (s, 2H), 7.52-
7.62 (m, 3H), 7.70 (t, J = 7.8 Hz, 1H), 8.05-8.10 ppm (m, 4H). IR:  1680 cm-1. 
2-(4-Bromo-2-nitrophenyl)-1-phenylethanone (67). Synthesized as 66, starting from 64. Yield 40%, 
mp 114-116 °C (from ethanol). 1H NMR (DMSO-d6):  4.87 (s, 2H), 7.53-7.60 (m, 3H), 7.70 (t, J = 7.1 
Hz, 1H), 7.96-7.98 (m, 1H), 8.05 (d, J = 7.4 Hz, 2H), 8.28-8.30 ppm (m, 1H). IR:  1686 cm-1. 
2-(4-Fluoro-2-nitrophenyl)-1-phenylethanone (68). Synthesized as 66, starting from 65. Yield 16%, 
mp 95-98 °C (from ethanol). 1H NMR (DMSO-d6):  4.88 (s, 2H), 7.56-7.72 (m, 5H), 8.03-8.06 ppm 
(m, 3H). IR:  1680 cm-1. 
General Procedure for the Preparation of 69-74. Example. N-(3-Chloro-2-
methylphenyl)benzamide (69). A solution of benzoyl chloride (7.93 g, 6.55 mL, 56 mmol) in anhydrous 
tetrahydrofuran (20 mL) was added dropwise to a solution of 3-chloro-2-methylaniline (6.68 g, 5.64 
mL, 47 mmol) and triethylamine (5.70 g, 7.85 mL, 56 mmol) at 0 °C in the same solvent (134 mL). 
The reaction was heated at reflux for 2 h. After cooling, the mixture was diluted with water and 
extracted with ethyl acetate. The organic layer was washed with brine, dried and filtered. Removal of 
the solvent gave a residue that was triturated with diethyl ether to furnish 69 (5.66 g, 49%), mp 168-
170 °C, Lit.54 170 °C. 1H NMR (CDCl3):  2.40 (s, 3H), 7.21 (t, J = 8.0 Hz, 1H), 7.26-7.29 (m, 1H), 
7.51-7.55 (m, 2H), 7.58-7.62 (m, 1H), 7.75-7.80 (m, 2H; one proton disappeared after treatment with 
D2O), 7.90-7.92 ppm (m, 2H). IR:  1647, 3244 cm-1. 
N-(3-Fluoro-2-methylphenyl)benzamide (70). Synthesized as 69, starting from 3-fluoro-2-
methylaniline. Yield 67%, mp 150-152 °C (from ethanol), Lit.55 157-158 °C. 1H NMR (CDCl3):  2.25 
(s, 3H), 6.93 (t, J = 9.0 Hz, 1H), 7.20-7.27 (m, 1H), 7.52 (t, J = 7.7 Hz, 2H), 7.59 (t, J = 7.3 Hz, 1H), 
7.71-7.75 (m, 2H; one proton disappeared after treatment with D2O), 7.88-7.91 ppm (m, 2H). IR:  
1670, 3230 cm-1. 
N-(3-Methoxy-2-methylphenyl)benzamide (71). Synthesized as 69, starting from 3-methoxy-2-
methylaniline. Yield 82%, mp 173-175 °C (from ethanol), Lit.56 177 °C. 1H NMR (DMSO-d6):  2.06 
(s, 3H), 3.82 (s, 3H), 6.89 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 7.8 Hz, 1H), 7.19 (t, J = 8.1 Hz, 1H), 7.53 (t, 
J = 7.6 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.98 (d, J = 7.2 Hz, 2H), 9.89 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  1649, 3229 cm-1. 
N-(5-Chloro-2-methylphenyl)benzamide (72). Synthesized as 69, starting from 5-chloro-2-
methylaniline. Yield 58%, mp 125-127 °C (from ethanol), Lit.57 121-123 °C.  
N-(5-Methoxy-2-methylphenyl)benzamide (73). Synthesized as 69, starting from 5-methoxy-2-
methylaniline. Yield 88%, mp 113-115 °C (from ethanol). 1H NMR (DMSO-d6):  2.17 (s, 3H), 3.74 (s, 
3H), 6.77 (dd, J = 2.6 and 8.4 Hz, 1H), 6.98 (d, J = 2.6 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 7.53 (t, J = 
7.6 HZ, 2H), 7.59 (t, J = 7.3 Hz, 1H), 7.98 (d, J = 7.1 Hz, 2H), 9.83 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  1650, 3299 cm-1. 
N-(2-Methoxy-6-methylphenyl)benzamide (74). Synthesized as 69, starting from 2-methoxy-6-
methylaniline. Yield 82%, mp 127-130 °C (from ethanol). 1H NMR (DMSO-d6):  2.50 (s, 3H), 3.74 (s, 
3H), 6.87-6.93 (m, 2H), 7.20 (t, J = 8.0 Hz, 1H), 7.49-7.60 (m, 3H), 8.00 (d, J = 7.3 Hz, 2H), 9.57 ppm 
(broad s, disappeared on treatment with D2O, 1H). IR:  1647, 3360 cm-1. 
General Procedure for the Preparation of 75-80. Example. 1-(4-Bromophenyl)-2-(1-
phenylethylidene)hydrazine (75). A mixture of 4-bromophenylhydrazine hydrochloride (3.35 g, 15 
mmol), acetophenone (1.20 g, 1.16 mL, 10 mmol) and sodium acetate (1.23 g, 15 mmol) in ethanol (15 
mL) was placed into the microwave cavity (open vessel mode). Microwave irradiation of 250 W was 
used, the temperature being ramped from 25 °C to 80 °C. Once 80 °C was reached, taking about 1 min, 
the reaction mixture was held at this temperature for 5 min, while stirring and cooling. The reaction 
mixture was cooled to 0 °C, filtered, washed with petroleum ether and dried to give 76 (0.90 g, 30%), 
mp 118-120 °C (from ethanol). 1H NMR (CDCl3):  2.25 (s, 3H), 7.08 (d, J = 8.9 Hz, 2H), 7.35-7.41 
(m, 6H; one proton disappeared after treatment with D2O), 7.83 ppm (d, J = 8.5 Hz, 2H). IR:  3353 
cm-1. 
1-(4-Chlorophenyl)-2-(1-phenylethylidene)hydrazine (76). Synthesized as 75, starting from 4-
chlorophenyl hydrazine hydrochloride. Yield 25%, mp 105-107 °C (from ethanol), Lit.58 100-102 °C. 
1H NMR (CDCl3):  δ 2.25 (s, 3H), 7.12 (d, J = 8.8 Hz, 2H), 7.24 (d, J = 8.8 Hz, 2H), 7.31-7.35 (m, 
2H; one proton disappeared after treatment with D2O), 7.40 (t, J = 7.0 Hz, 2H), 7.79 ppm (d, J = 7.1 Hz, 
2H). IRμ Ȟ 3352 cm-1. 
1-(4-Fluorophenyl)-2-(1-phenylethylidene)hydrazine (77). Synthesized as 75, starting from 4-
fluorophenyl hydrazine hydrochloride. Yield 95%, mp 110-112 °C (from ethanol), Lit.59 107 °C. 1H 
NMR (DMSO-d6)μ δ 2.25 (s, 3H), 7.00-7.10 (m, 2H), 7.22-7.29 (m, 3H), 7.38 (t, J = 7.3 Hz, 2H), 7.78 
(d, J = 7.2 Hz, 2H), 9.31 ppm (broad s, disappeared on treatment with D2O, 1H). IRμ Ȟ 3380 cm-1. 
1-(2-Bromophenyl)-2-(1-phenylethylidene)hydrazine (78). Synthesized as 75, starting from 2-
bromophenyl hydrazine hydrochloride. Yield 86%, mp >300 °C (from ethanol). Spectral data were 
consistent with those reported in Lit.60 
1-(2-Fluorophenyl)-2-(1-phenylethylidene)hydrazine (79). Synthesized as 75, starting from 2-
fluorophenyl hydrazine hydrochloride. Yield 68%, mp >300 °C (from ethanol). 1H NMR (DMSO-d6): 
 2.32 (s, 3H), 6.79-6.84 (m, 1H), 7.13-7.17 (m, 2H), 7.34-7.43 (m, 3H), 7.56-7.59 (m, 1H), 7.80-7.83 
(m, 2H), 8.64 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3380 cm-1. 
1-(2,3-Dichlorophenyl)-2-(1-phenylethylidene)hydrazine (80). Synthesized as 75, starting from 2,3-
dichlorophenyl hydrazine hydrochloride. Yield 79%, mp 112-115 °C. 1H NMR (DMSO-d6):  2.36 (s, 
3H), 7.09 (dd, J = 1.4 and 7.9 Hz, 1H), 7.31 (t, J = 8.4, 1H), 7.37-7.45 (m, 3H), 7.60 (dd, J = 1.3 and 
8.4 Hz, 1H), 7.84-7.87 (m, 2H), 8.40 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  
3270 cm-1. 
Molecular Modeling. All molecular modeling studies were performed on a MacPro dual 2.66GHz 
Xeon running Ubuntu 14. The tubulin structure was downloaded from the PDB data bank 
(http://www.rcsb.org/, PDB code: 1SA0).6 Ligand structures were built with MOE61 and minimized 
using the MMFF94x forcefield until a RMSD gradient of 0.05 kcal mol-1 Å-1 was reached. The docking 
simulations were performed using PLANTS18 on the 1SA0 crystal structure. 
 
Biology. Tubulin Assembly. The reaction mixtures contained 0.8 M monosodium glutamate (pH 
6.6 with HCl in a 2 M stock solution), 10 ȝM tubulin, 4% (v/v) DMSO and varying concentrations of 
drug. Following a 15 min preincubation at 30 °C, samples were chilled on ice, GTP to 0.4 mM was 
added, and turbidity development was followed at 350 nm in a temperature controlled recording 
spectrophotometer for 20 min at 30 °C. Extent of reaction was measured. Full experimental details 
were previously reported.62 
[3H]Colchicine Binding Assay. The reaction mixtures contained 1.0 ȝM tubulin, 5.0 ȝM 
[3H]colchicine, and 5.0 ȝM inhibitor and were incubated 10 min at 37 °C. Complete details were 
described previously.63 
Cell Cultures. Cell lines were obtained from the American Type Culture Collection (ATCC), unless 
otherwise specified. MCF-7 breast carcinoma, OVCAR-8, and NCI/ADR-RES cells were obtained 
from the National Cancer Institute drug screening laboratory, and NB4 cells and MV4-11 cells from the 
Deutsche Sammlung von Mikroorganismen und Zellkulturen. All cell lines, except as indicated, were 
grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), 20 mM HEPES, 100 U/mL penicillin, 100 mg/mL streptomycin and 1% L-glutamine; specific 
requirements include the addition of sodium pyruvate (1-2% for RD rhabdomyosarcoma, HepG2 
hepatoma and the three MDA breast carcinoma cell lines) and glucose (1 g/L for RD and HepG2, 4.5 
g/L for PC3 prostate carcinoma).  Cell lines were cultured at 37 °C in 5% CO2-95% air in a humidified 
incubator. Treatments were initiated 24 h after cell seeding using ATI compound diluted in 0.1% 
DMSO, or the indicated reference compound, or 0.1% DMSO vehicle, for 24-72 h as indicated.  
Cell Viability Assays. MCF-7 breast carcinoma and OVCAR-8 and NCI/ADR-RES ovary 
carcinoma cells: methodology for evaluation of growth was previously described, except that cells were 
grown for 96 h for IC50 determinations.64 
MV4-11, NB4, A-549, NCI-H1975, Messa and Messa/Dx5: cells were seeded into 96-well plates 
(Corning Inc., Costar) at a density of 2x103 cells/well in 50 ȝL of the appropriate medium. MDA-MB-
468, MDA-MB-436 and MDA-MB-231 breast carcinoma cell lines: cells were plated in 100 µL 
medium in 96-well plates at a density of 3.5 x 103 per well for MDA-MB-468, 3 x 103 per well for 
MDA-MB-436 and 2 x 103 per well for MDA-MB-436. After 24 h, cells were treated with the inhibitor 
(100 nM to 0.39 nM) and then evaluated in MTT assays as described.65 Statistical analysis was 
performed by analysis of variance (ANOVA) with Neumann-Keul's multiple comparison test or 
Kolmogorov-Smirnov where appropriate. 
PC-3, HepG2 and RD cell lines: cells were seeded in 24-well plates at a density of 95x103/100 ȝL 
well (PC-3 and RD), or 120x103/100 ȝL well (HepG2). After 24 h, the test compound was added (0.01-
25 M) for 48 h. After removal of the medium, MTT was added (500 ȝM final concentration in 500 
ȝL/well of phosphate-buffered saline; PBS) and incubation continued at 37 °C for 2 h in the dark. The 
formazan crystals were dissolved in isopropanol containing 0.04 N HCl (200 ȝL). A550 in the wells was 
determined using a Multiskan Spectrum Thermo Electron Corporation reader. IC50 values were 
calculated by nonlinear regression analysis (GraphPad Prism statistics software). Experiments were 
performed in triplicate. HeLa cells: 7x103 cell-aliquots were seeded in a flat-bottom 96-well tissue 
culture plate and, after 24 h, were exposed to the inhibitor (10-100 nM) for 24 L, 5 
mg/mL) (Sigma-Aldrich) was added to each well and cells were further incubated for 3 h at 37 °C. 
After solubilization of the crystals with isopropanol/0.04 N HCl, A570 measurements were made with 
an ELISA reader, and IC50 values were derived from dose-response curves. 
MV4-11, NB4 (AML), A-549 and NCI-H1975 (lung adenocarcinoma) cell lines: cell growth was 
measured using
 
CellTiter-Flor® (Promega), a nonlytic, single-reagent-addition fluorescence assay that 
detects the relative number of living cells in samples after experimental manipulation. The CellTiter-
Fluor™ Cell Viability Assay measures the conserved and constitutive protease activity within live cells 
and, therefore, acts as a marker for cell viability. NB4 and MV4-11 cells in exponential growth were 
incubated for 48 h with different concentrations of the inhibitors. After 48 h, CellTiter-Fluor® Reagent 
was added to the cell culture medium (1:1 vol/vol) and incubated for at least 90 min at 37 C. A549 and 
NCI-H1975 cells were treated with the inhibitor for 72 h, then CellTiter-Fluor® Reagent was added to 
one fifth of the culture medium volume. Fluorescence was recorded (excitation wavelength, 360 nm; 
emission wavelength, 535 nm), and the IC50 was calculated using GraphPad Software. 
Messa and Messa/Dx5 (resistant) sarcoma cell lines: the CellTiter-Glo luminescent cell viability 
assay was used (Promega, Madison, WI). Cells in exponential growth were incubated for 72 h with 
different concentrations of the inhibitor, then the same volume of CellTiter-Glo reagent was added. The 
solution was stirred for 2 min to induce cell lysis. Luminescence was recorded after an additional 10 
min. IC50 values were calculated using nonlinear regression analysis (GraphPad Prism statistics 
software). 
T98G and U343MG cells: growth was measured by a colorimetric MTS conversion assay, as 
previously reported.15 
D283 medulloblastoma cells: 3x105 D283 cells/well were plated in a 24-multiwell dish. After 24 h, 
ATI derivative 44 or 81 (1 ȝM) was added to the cells for the indicated time. Viability was evaluated 
with a trypan blue assay. 
Antibodies and Immunostaining. The following unconjugated monoclonal antibodies (mAbs) 
were used for immunostaining: anti-MICA (MAB159227), anti-MICB (MAB236511), anti-ULBP1 
(MAB170818), anti-ULBP2 (MAB165903) and anti-ULBP3 (MAB166510) from R&D Systems 
(Minneapolis, MN); anti-PVR (SKII.4) kindly provided by Prof M. Colonna (Washington University, 
St Louis, MO); anti-Nec-2 (R2.525) from BD Pharmingen (San Diego, CA); allophycocyanin (APC)-
conjugated goat affinity purified F(ab’)2 fragment to mouse IgG (GAM) from Jackson 
ImmunoResearch Laboratories (West Grove, PA). 
Flow Cytometry Analysis. 3x105 HeLa cells were seeded in tissue culture dishes. After ATI 
treatment, cell numbers were counted using a Z1 Coulter Particle Counter (Beckman Coulter). Cell 
cycle phase distribution was analyzed in permeabilized cells incubated with PI (Sigma Aldrich P4170, 
0.04 mg/ml). SS and FL-3 parameters were acquired in a linear amplification scale, FS and Fl2, in a log 
scale. Cell aggregates were gated out on the bi-parametric graph FL-3lin/Ratio. Apoptosis was 
determined as the proportion of cells exhibiting a DNA content lower than 2N after gating out cell 
debris on the bi-parametric graph FS/SS using the WinMDI software. Cell death was analyzed in 
200,000 cell-aliquots in binding buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) 
incubated with annexin V-FITC (Immunological Sciences, IK-11120) alone or annexin V-FITC in 
combination with PI in the absence of permeabilizing agents. Cell samples were analyzed in a Coulter 
Epics XL cytofluormeter (Beckman Coulter) equipped with EXPO 32 ADC software. At least 10000 
cells per sample were acquired. 
IF and Image Analysis. Cells were seeded on sterile polylysine-coated coverslips placed in tissue 
culture plates. After treatment with ATI or VBL, as indicated, the cells were fixed with 3.7% 
paraformaldehyde in PBS for 10 min at room temperature and then permeabilized in 0.1% Triton-X100 
in PBS for 5 min. Blocking and antibody reactions were carried out in PBS/0.05% Tween 20 
containing 3% BSA at room temperature using mouse anti-alpha-tubulin (1:2000, B-5-1-2, Sigma-
Aldrich) followed by FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories). 
Chromosomal DNA was stained with 4,6-diamidino-2-phenylindole (DAPI, 0.1 µg/mL) and mounted 
in Vectashield (Vector Laboratories). Images were analyzed using a Nikon Eclipse 90i microscope 
equipped with a Qicam Fast 1394 CCD camera (Qimaging). To resolve MT remnants or unstructured 
tubulin foci, some of the acquired images were deconvoluted and analyzed using the Extended Depth 
of Focus on Z-serial optical sections using Nis-Elements AR 4.2 (Nikon). 
IF and Flow Cytometry Ligand Analysis. The expression of NKG2D and DNAM-1 ligand surface 
expression on HeLa cells was analyzed by IF staining using anti-MICA, anti-MICB, anti-ULBP1/2/3, 
anti-PVR or anti-Nec2 unconjugated mAbs, followed by secondary GAM/APC. Samples were 
analyzed using a FACSCanto II (BD Biosciences, San Jose, CA). Flow cytometric analysis was 
performed using the FlowJo software version 8.8.7 (TreeStar, Ashland, OR). 
Degranulation Assay. NK cell-mediated cytotoxicity was evaluated using the degranulation 
lysosomal marker CD107a as previously described.66 As a source of effector cells, we used human 
peripheral blood mononuclear cells (PBMCs) isolated from healthy donors by Lymphoprep (Nycomed, 
Oslo, Norway) gradient centrifugation and then co-cultured for 10 days with an irradiated (30 Gy) 
Epstein-Barr virus (EBV)-transformed B-cell line. Cells were grown in RPMI 8866 at 37 °C in a 
humidified 5% CO2 atmosphere. On day 10, the cell population was routinely more than 90% 
CD56+CD16+CD3-, as assessed by IF and flow cytometric analysis. After a 48 h treatment with 33 or 
44, HeLa cells were incubated with activated NK cells at effector:target (E:T) ratios of 1:1 in a flat-
bottom 96-well tissue culture plate in complete medium (DMEM (Life Technologies, Gaithersburg, 
MD) supplemented with 10% FCS). The plates were incubated at 37 °C in a 5% CO2 atmosphere for 2 
h. Thereafter, cells were washed with PBS and incubated with anti-CD107a/APC (or cIgG/APC) for 45 
min at 4 °C. Cells were also stained with anti-CD3/FITC and anti-CD56/PE to gate the CD3-CD56+ 
NK cell population. 
Real-time PCR. MICA, MICB, ULBP1, ULBP2, and ULBP3 and PVR mRNA expression was 
analyzed by real-time PCR. Total RNA from HeLa cells was extracted using Trizol (Invitrogen) after a 
maximum of 24 h of drug treatment. Total RNA (1 g) was used for cDNA first-strand synthesis using 
oligo-dT (Promega, Madison, WI) in a 25 L reaction volume. To analyze ligand mRNA expression, 
the cDNA was amplified in triplicate with the following primers: Hs00792952_m1 for MICA, 
Hs00792952_m1 for MICB, Hs00197846_m1 for PVR, Hs00607609_m1 for ULBP2, 
Hs00225909_m1 for ULBP3, and Hs99999903_m1 for -actin, all conjugated with fluorochrome FAM 
(Applied Biosystems). The level of ligand expression was measured using the Threshold Cycle value 
(Ct). The ∆Ct was obtained by subtracting the Ct value of the gene of interest (MICA, MICB or PVR) 
from the housekeeping gene (-actin) Ct value. We used ∆Ct of NT sample as the calibrator. The fold 
change was calculated according to the formula 2-∆∆Ct, where ∆∆Ct was the difference between ∆Ct of 
the sample and that of the calibrator (according to the formula, the value of the calibrator in each run is 
1). 
Hh-dependent Luciferase Reporter Assay. The luciferase assay was performed in Shh-Light II 
(Shh-L II) cells, stably incorporating a Gli-responsive luciferase reporter and the pRL-TK Renilla 
(normalization control), treated for 48 h with SAG (200 nM) and the studied compounds. Luciferase 
and renilla activity were assayed with a dual-luciferase assay system according to the manufacturer’s 
instructions (Promega, Madison, WI, USA). Results are expressed as luciferase/renilla ratios and 
represent the mean ± SD of three experiments, each performed in triplicate. 
LC-MS/MS Analytical method. Samples were analyzed under the following conditions: UFLC 
(Shimadzu) AC20 coupled with a API 3200 Triple Quadrupole (ABSciex); eluents, phase A: 95% 
water, 5% acetonitrile + 0.1% HCOOH, phase B: 5% water, 95% acetonitrile + 0.1% HCOOH; flow 
rate, 0.3 mL/min; column, Gemini - Nx 5µ C18 110A (50*2.00 mm) at 35 °C; injection volume, 5 µL. 
LC–MS/MS analyses were carried out using an ESI(+) interface in multiple reaction monitoring mode. 
Metabolic Stability. Compounds 33 and 44 were dissolved in DMSO in duplicate at a final 
concentration of 1 µM and preincubated for 10 min at 37 °C in potassium phosphate buffer pH 7.4, 3 
mM MgCl2, with human or mouse liver microsomes (Xenotech) at a final concentration of 0.5 mg/mL. 
After the preincubation period, reactions were started by adding the cofactors mixture (NADP, Glc6P, 
G6P-DH). Samples were taken at times 0, 10, 20, 30 and 60 min. Acetonitrile was added to stop the 
reaction and centrifuged. Supernatants were analyzed and quantified by LC-MS/MS. A control sample 
without cofactors was always added in order to check the stability of test compounds in the reaction 
mixtures. The reference standards were 7-ethoxycoumarin and propranolol. A fixed concentration of 
verapamil was added in every sample as an internal standard for LC-MS/MS. The percent of the area of 
test compound remaining at the various incubation times were calculated with respect to the area of 
compound at time 0 min.  
The rate constant, k (min-1) derived for the exponential decay equation (peak area/IS vs time) was 
used to calculate the rate of intrinsic clearance (CL) of the compound using the following equation: 
 
CL (L/min/mg protein) = k/microsomal conc. x 103 
 
Aqueous Solubility. The solubilities of compounds 33 and 44 were measured using a high 
throughput screening assay format. Samples prepared at the target concentration of 200 M were 
placed in a 96-well filter plate and incubated at room temperature for 90 min. The plate was then 
filtered, and solutions were analyzed by LC-MS/MS. Final concentrations were evaluated by 
comparing the area under the curve of the MeOH stock solution with those of the test compound 
solutions. 
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